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ABSTRACT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION BY POLYCHLORINATED
BIPHENYLS CONTRIBUTES TO NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Josiah E. Hardesty
August 20th 2018

This dissertation describes how poly-chlorinated biphenyls (PCBs) exacerbate the
pathogenesis of non-alcoholic fatty liver disease (NAFLD). While PCBs were banned in 1979, they
still persist in contaminated biota, including food, and are detected in human plasma and adipose.
The body burden of PCBs is associated with elevation of liver enzymes and necrosis markers in
humans, characteristic of NAFLD. PCB exposure in high-fat diet fed mice leads to steatohepatitis
that recapitulate the findings seen in exposed humans. The global estimate of people diagnosed
with NAFLD is up to 1 in 4 people, unrelated to dietary or genetic factors. The hepatic mechanisms
most commonly associated with PCB exposures are xenobiotic nuclear receptor activation,
followed by changes in xenobiotic metabolism. Other processes must be involved since highly
chlorinated PCB congeners are not metabolized and are long-lived in the body.

A novel PCB target was elucidated and characterized, being the epidermal growth factor
receptor (EGFR). New effectors downstream of EGFR, including NRF2 and HNF4a, were identified
and verified. The basic biology of EGFR signaling in the liver was observed, including regulation of
glutathione synthesis, gluconeogenesis, and lipid metabolism. A novel therapy for NAFLD was
elucidated in this dissertation, as well, which is therapeutically promising, since no available
therapies for NAFLD exist.
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I hypothesize that PCBs act through inhibition of EGFR action promoting NAFLD. The first
finding in this work was that PCBs inhibit EGFR signaling in vivo and in vitro. Next PCBs and other
chlorinated compounds were found to prevent EGF-EGFR endocytosis in cell-based assays. The
third finding demonstrates that in PCB-mediated steatohepatitis, EGFR-NRF2 and EGFR-HNF4a
signaling pathways are downregulated, while fibrogenic pathways are upregulated. PCBs were
shown to severely disrupt multiple signaling pathways in PCB-mediated liver disease including a
loss of 25% of phospho-peptides involved in cellular regulation.

Epidermal growth factor (EGF) administration prevented PCB-mediated steatohepatitis
and bridging fibrosis, two of the crucial stages of NAFLD. This dissertation is unique in that a
mechanism of action for PCBs through EGFR inhibition was characterized biochemically, followed
by evaluation of an effective therapeutic intervention that may impact human health interventions
for NAFLD.
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CHAPTER 1
INTRODUCTION
NAFLD is a spectrum of diseases ranging from simple steatosis (lipid accumulation) which
can progress to steatohepatitis (chronic inflammation). This can progress further to liver fibrosis
and ultimately liver failure or hepatocarcinoma. Currently 25% of the global population fall
somewhere on the spectrum of NAFLD (Figure 1). While obesity is a global epidemic it does not
fully explain the 25% prevalence of NAFLD worldwide (1). Obesity would primarily explain hepatic
steatosis, but many patients progress to later stages of NAFLD without a direct explanation.
Steatosis is the result of an imbalance of lipid uptake vs. oxidation resulting in hepatic lipid droplet
formation and accumulation. Steatohepatitis is a state of chronic inflammation in the liver where
immune cells are responsive but cannot efficiently clear the abundant dead hepatocytes leading to
secondary necrosis (2). Chronic steatohepatitis can activate hepatic stellate cells (HSCs) which
deposit collagen leading to scarring or cirrhosis. Late stage NAFLD can end in liver failure or
hepatocellular carcinoma (HCC). Non-alcoholic steatohepatitis (NASH) is a subset of NAFLD that
is not due to alcohol (alcoholic steatohepatitis/ASH) or chemicals exposure (toxicant associated
steatohepatitis/TASH). NASH has been shown to be exacerbated by loss of gut barrier function
leading to endotoxemia, and dietary stress such as a high fat diet (HFD). No matter the subset of
NAFLD a majority of animal models are built upon a two-hit hypothesis for NAFLD. Where one
stressor alone will not promote NAFLD but requires two such as alcohol and lipopolysaccharide
(LPS). For TASH models a HFD in combination with the chemical exposure is required to elicit
progression from steatosis to steatohepatitis (3). The HFD alone has been shown to promote insulin
resistance and promote steatosis. Chemicals such as PCBs can in turn promote hepatic necrosis
in combination with a HFD and has been coined TASH (4, 5).
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Figure 1. The NAFLD spectrum
Figure 1 illustrates the stages of NAFLD ranging from left to right simple steatosis, NASH, cirrhosis,
and HCC. Figure 1B demonstrates the histological changes ate each stage of NAFLD from top to
bottom steatosis, NASH, and cirrhosis. This figure is adapted from Cohen et al 2011(6).

2

PCBs were mass produced as highly chlorinated mixtures under the brand name Aroclor
from 1930 to 1977 by Monsanto in the US. PCBs, like most chemicals, were developed solely for
their chemical properties. PCBs have a high thermostability and were used to insulate transformers
and electrical equipment as they maintain their structure and chemical properties under high
electrical current. The chlorine carbon bonds give PCBs a high thermal stability and in turn make
these chemicals hydrophobic. PCBs were ultimately banned from production in the US in the 1970s
due to their carcinogenic effects in rodents (7). Although they have been banned from production
for many years they still persist in the environment and are detected in humans due to propagation
by consumption of contaminated biota (8). There are 209 theoretical PCB congeners that are
chlorinated biphenyls with varying amounts of chlorination based on the congener (9). The chlorine
positions alter the structure of the PCB leading to two major classes of PCBs. PCBs fit into either
non-dioxin like PCBs which are noncoplanar or the dioxin-like PCBs which are coplanar (Figure 2).
There have been many adverse effects associated with PCB exposures over the years, but
metabolic diseases are a growing concern. Environmental chemical exposures are often
overlooked and unfortunately the last factor considered as contributing to a patient’s disease
phenotype. This is somewhat disturbing since 100% of National Health and Nutrition Examination
Survey (NHANES) participants that had polychlorinated biphenyls (PCBs) measured in serum had
detectable levels (10). In the NHANES population increasing body burdens of PCBs are associated
with elevated ALTs which is a proxy marker for NAFLD (10). It is important to note that these
participants are randomly selected and are not a highly exposed cohort such as the Anniston, AL
cohort who reside where PCBs were manufactured in the US. Other human exposures to PCBs
outside of the US have occurred as well including the Yusho (Japan 1968) and Yu-Cheng (Taiwan
1979) PCB poisonings where rice oil was contaminated with PCBs. Follow-up studies of these
cohorts have demonstrated increased mortality to liver disease and increased incidence of diabetes
relative to non-exposed populations (11, 12).

Within the Anniston cohort there is a strong

association with elevated PCB body burden and elevated liver necrosis biomarker cytokeratin-18
(CK-18), suggestive of steatohepatitis (13). PCB exposure within these two genetically distinct
populations have been associated with NAFLD (10, 12, 14). While there is strong evidence
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demonstrating that PCB exposures in humans can promote NAFLD the mechanisms remain illdefined.
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Figure 2. Chemical structure of PCB-126 (dioxin like PCB) and PCB-180 (non-dioxin like
PCB): Figure 2 illustrates the chemical structure of PCB-126 (left) and PCB-180 (right). PCB-126
is co-planar and considered a dioxin-like PCB whereas PCB-180 is non-co-planar and considered
a non-dioxin like PCB. Both PCBs have a carbon biphenyl ring structure (gray) with varying
numbers of chlorine (green) and in various positions. The biphenyl rings for PCB-126 are in the
same plane (coplanar) but PCB-153 have the biphenyl rings in different planes (non-coplanar) due
to the positioning of the chlorine atoms.
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Primary studies of PCBs effects on gene transcription demonstrated two key responses
that can be explained by the congener type. Dioxin-like (DL) congeners elicit an aryl hydrocarbon
receptor (AhR) mediated response while non-dioxin like (NDL) PCBs give rise to a constitutive
androstane receptor (CAR) or pregnane x receptor (PXR) mediated responses (9). Both of these
responses are a part of xenobiotic metabolism and thus activation of these pathways does not
explain how they would cause progressive hepatic necrosis and NAFLD. In fact, activation of
xenobiotic metabolism would be considered positive for clearance of PCBs but unfortunately there
are no endogenous enzymes to metabolize certain PCBs and some highly chlorinated congeners
have 18 year half-lives (15). In fact, direct activation of CAR can ameliorate diet induced NAFLD
(16, 17). PCBs increase hepatic CAR target gene expression in rodents robustly but even in the
absence of CAR animals still develop steatohepatitis upon a HFD and PCB exposure (18). This
would suggest that PCBs do more than just activate xenobiotic receptors such as CAR. Previous
studies with Phenobarbital demonstrate that CAR can be indirectly activated by epidermal growth
factor receptor inhibition (19) (Figure 3). Phenobarbital and NDL PCBs have been shown to elicit
similar hepatic responses and could both be acting through EGFR inhibition (20-22).

6

Figure 3. Model of EGFR inhibition leading to indirect CAR activation: Figure 3 illustrates a
mechanism for phenobarbital and potentially PCBs to indirectly activate CAR through inhibition of
EGFR leading to loss of protein phosphorylation and CAR activation. This figure is adapted from
Negishi 2017(23).
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EGFR is a receptor tyrosine kinase that is highly expressed in the liver. Upon ligand binding
the EGFR will dimerize and autophosphorylate leading to downstream activation or inactivation of
kinases, enzymes, and transcription factors through protein phosphorylation (24, 25). Upon
autophosphorylation the active EGFR complex will undergo endocytosis and eventually the signal
will be attenuated, and the receptor recycled. Some downstream kinases of EGFR include PI3K,
ERK, AKT, and mTOR which are implicated in regulation metabolism through enzyme
phosphorylation (24). EGFR has been shown to have many roles in development and tissue
homeostasis such as in skin and gastrointestinal tract tissue homeostasis (26). EGFR signaling
maintains tissues with high cellular turnover through growth and proliferation mediated pathways.
EGFR is most heavily implicated in cancer where EGFR mutations can promote more aggressive
cancers (27). Many EGFR inhibitors have been manufactured and used as effective cancer
therapeutics. There are many studies demonstrating EGFR’s role in pathological disease states
like cancer but very few that study the physiological role of EGFR in adult metabolism. Recently
EGFR has been implicated in adult liver homeostasis (28). While EGFR is highly expressed in the
liver and 60% of labeled EGF traffics to the liver little is known about its role in liver function and
homeostasis (29). Recently EGFR signaling has been shown to peak in the inactive phase in
murine liver suggesting it may be integral for fasting responses in the liver (28) (Figure 4). Some
data demonstrate that attenuation of EGFR signaling can promote NAFLD (30, 31). Research in
alcoholic liver disease models suggest that EGF administration can prevent inflammation (32).
Previous work has demonstrated that placenta EGFR phosphorylation is downregulated in
pregnant mothers exposed to PCBs relative to non-exposed mothers following the Yu-Cheng
poisoning (33). While this is mechanistic evidence for PCB-mediated inhibition of placenta EGFR
and not hepatic EGFR follow-up studies of this cohort demonstrate increased mortality due to liver
disease (11, 12).
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Figure 4. EGFR signaling pathway in the liver peaks in the inactive phase: Figure 4
illustrates the circadian phosphoproteome in murine liver. EGFR regulated phospho-sites peak
during the inactive phase (yellow) whereas insulin receptor (IR) regulated sites peak during the
active phase (blue). This data suggests that EGFR signaling may be critical for many hepatic
functions during the inactive phase in organisms. This figure was adapted from the original figure
that is attributed to Robles et al 2017(28).
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These human and animal findings demonstrate the necessity to determine how
environmental PCB exposures progress NAFLD in combination with hypercaloric intake. Since
PCB exposures are extensive and can progress steatosis to steatohepatitis in mice it may be a
critical factor in the rising rates of NAFLD worldwide. While the association between PCB
exposures, diet, and NAFLD progression are heavily intertwined no real mechanism has been
elucidated to explain the disease phenotype. With the following taken into consideration; 1) strong
association with NAFLD and PCB exposure, 2) CAR-null mice still develop TASH with PCB
exposure, and 3) PCBs prevent placenta EGFR phosphorylation I aimed to investigate 1)whether
PCBs act through EGFR inhibition to promote NAFLD, 2) characterize the PCB disrupted
proteome and phosphoproteome, and 3) determine if epidermal growth factor (EGF)
administration ameliorates PCB-mediated steatohepatitis.
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CHAPTER 2
POLYCHLORINATED BIPHENYLS DISRUPT HEPATIC EPIDERMAL GROWTH FACTOR
RECEPTOR SIGNALING
INTRODUCTION
Polychlorinated biphenyls (PCBs) are lipid-soluble, persistent organic pollutants that
preferentially accumulate in visceral adipose tissue and liver (34). Previously, PCBs were used in
industrial applications such as heat exchangers and electrical capacitors. PCBs were manufactured
as mixtures based on chlorine content, rather than as individual congeners. The PCB mixture,
Aroclor 1260 (Monsanto Company, US), contains 60% chorine by weight, and its composition is
similar to human adipose bioaccumulation patterns (35, 36). Daily human PCB consumption is
estimated to be 30 ng/day (37), but is likely to be greater in people eating highly contaminated
foods, such as fish from polluted waterways. Higher chlorinated PCB congeners such as PCB-180
have a half-life of 11.5 years and thus could chronically alter signaling pathways involved in
metabolic disorders (15). As a result, 100% of US adult participants in the National Health and
Nutrition Examination Survey (NHANES) had detectable levels of PCBs in serum (10). In humans,
PCBs have been associated with metabolic diseases including nonalcoholic fatty liver disease
(NAFLD) (10, 38-40), obesity (41), hypertension (42), diabetes (11, 43, 44), and dyslipidemia (45).
Animal models document the development of NAFLD and its more severe form, nonalcoholic
steatohepatitis (NASH), following PCB treatment (3). In fact, PCBs were among the most potent
environmental chemicals associated with NAFLD in rodents (46). Determining mechanisms by
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which PCBs may contribute to NAFLD pathogenesis is the overall objective of this
dissertation. Historically, PCB congeners have been classified by structure-activity relationships
based on their observed effects on hepatic xenobiotic metabolism (9). “Dioxin-like” PCBs increase
ethoxyresorufin

O-deethylase

activity

(47),

while

“phenobarbital-like”

PCBs

increase

pentoxyresorufin O-dealkylase activity. PCBs were subsequently noted to activate xenobiotic
receptors including the aryl hydrocarbon receptor (AhR), the pregnane X receptor (PXR), and the
constitutive androstane receptor (CAR) leading to the induction of specific cytochrome P450
enzymes including CYP1A, CYP3A, and CYP2B, respectively (3, 48). While PCB-nuclear receptor
interactions influenced intermediary metabolism in an animal model of NASH (18), exposure to
PCBs alone was insufficient to cause NASH, but rather served as a ‘second hit’ in the transition of
diet-induced steatosis to steatohepatitis (3). Aroclor 1260 treated Car-/- mice fed a high fat diet
(HFD) had increased activity, decreased food consumption, and increased insulin sensitivity
compared to wild type mice also fed HFD (18). However, NASH pathology did not improve
concordantly with these favorable metabolic changes in Car-/-. This suggests that while PCB-Car
interactions are important in metabolic syndrome, other mechanisms must also be important for
PCB-related NAFLD.

CAR may be activated either directly or indirectly by xenobiotics. The mechanism of CAR
activation may be important, because indirect CAR activation could be associated with additional
‘off target’ effects influencing NAFLD. I observed that PCBs directly activated human CAR (hCAR)
splice variants 2-3 but not hCAR1 (36). Although mouse CAR (mCAR) is homologous to hCAR1,
mice treated with PCBs displayed increased Cyp2b10 expression (3). The reasons for the varied
responses observed by these homologous proteins is most likely due to splice variants 2 and 3
having slightly larger ligand binding pockets allowing for additional space for ligand binding.
Phenobarbital is a prototypical Cyp2b10 inducer, and the indirect mechanism by which
phenobarbital activates CAR has recently been discovered (19). Phenobarbital prevented
epidermal growth factor (EGF) binding to its receptor (EGFR) inhibiting the phosphorylation
cascade leading to an increased abundance of dephosphorylated, active CAR.
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EGFR is a transmembrane receptor tyrosine kinase that is ligand-activated by the
epidermal growth factor (EGF) and other similar growth factors. Upon ligand binding, EGFR
dimerizes with itself or other family members. This induces activation of the receptor’s intrinsic
kinase activity, resulting in transphosphorylation of tyrosine residues on its receptor pair. These
newly formed phosphotyrosine residues serve as docking sites for downstream signaling proteins
(effectors) that act to modulate metabolic gene expression. Normal EGFR signaling is essential in
development and metabolism (49). In addition to CAR, downstream targets include the
phosphoinositol 3-kinase/serine/threonine kinase 1 or PKB/mechanistic target of rapamycin
(PI3K/Akt/mTOR) pathway, signal transducer and activator of transcription 3 (STAT3), serine and
threonine kinase (c-Raf) and extracellular signal-regulated kinase (ERK). Akt and mTOR are
effector kinases downstream of EGFR that regulate lipid metabolism, and glycogen synthesis (50,
51). Decreased EGFR signaling has been implicated in metabolic diseases such as type II diabetes
(52, 53) and NASH (25, 30-32, 54), both of which have been associated with PCB exposures (3,
10, 12, 14, 18, 55). Thus, I hypothesized that if PCBs antagonized EGFR like phenobarbital, this
effect could account for indirect CAR activation and the associated ‘off target’ effects contributing
to PCB-related NASH. Understanding how PCBs disrupt these pathways could provide mechanistic
insight into how PCBs mediate metabolic syndrome and liver disease (3, 56, 57). In this dissertation
I determine: (i) if PCB-mediated indirect CAR activation in mice is mediated by inhibition of EGFR
phosphorylation; (ii) if PCB effects on EGFR phosphorylation in mice are modified by diet; (iii) if
PCB-mediated

hypophosphorylation

of

EGFR

in

mice

impact

additional

downstream

phosphoprotein targets (including Akt and mTOR); and (iv) if PCBs also inhibit human EGFR
phosphorylation. I conclude from our studies that PCBs decrease phosphorylation of EGFR and its
downstream effector kinases.
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MATERIALS AND METHODS

Chemicals

1,4-Bis(3,5-dichloro-2-pyridyloxy)benzene (TCPOBOP) and androstanol were obtained from
Sigma Chemical Co., St. Louis, MO. Aroclor 1260, Aroclor 1254, and PCB congeners, PCB 3,
PCB 6, PCB 8, PCB 9, PCB 126, PCB 138, PCB 149, PCB 151, PCB 153, PCB 170, PCB 174,
PCB 180, PCB 187, were obtained from AccuStandard, Inc., New Haven, CT. Epidermal growth
factor (EGF) and EGFR inhibitor (EI, Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethylphenylamino)-pyrimidin-4-ylamino)-phenyl)-amide) were purchased from Millipore (Norwood, OH).
The following antibodies were used for Western blotting proteins from HepG2 and AML-12 cells:
EGFR (Santa Cruz, Santa Cruz, CA), P-EGFR Y1173 (abcam, Cambridge, MA), P-EGFR Y845
(abcam, Cambridge, MA), and P-EGFR Y1068, P-EGFR Y845, mouse liver EGFR, mTOR, PmTOR, AKT, P-AKT, STAT3, cRaf, ERK, P-ERK, β-actin, GAPDH (CST, Danvers, MA).

Cell culture

Alpha mouse liver 12 (AML-12) cells of male origin obtained from ATCC (Mannassas, VA), were
seeded at 1x104 per well in 12-well plates and grown to confluence for 24 hours in DMEM/F12 (GE
Healthcare, Pittsburgh, PA) media supplemented with 10% fetal bovine serum, and 1%
antimyotic/antibiotic solution.

The cells incubated in a 5% carbon dioxide atmosphere at 95%

humidity and 37°C were sub-cultured every 2-3 days. Cells were treated for 30 minutes with either
20 ng/mL of epidermal growth factor (EGF) (Fisher Scientific, Pittsburgh, PA) as a positive control,
20 ng/mL of EGF and 20 µg/mL EGFR inhibitor (EI) (CAS 879127-07-8) (Millipore, Norwood, OH)
as a negative control, or 20 ng/mL EGF and 20 µg/mL Aroclor 1260 (A1260). Aroclor 1260
concentration was used based on previous work demonstrating that in vitro concentrations higher
than 20 µg/ml were cytotoxic (Toxicity threshold = 26.7 ± 3.7 µg/mL in HepG2s)(36). The
concentration of EGF was optimal to induce EGFR phosphorylation, and EGFR inhibitor was used
at its IC50 concentration for EGFR dephosphorization. The 30-minute treatment was used as that
still produced robust EGFR phosphorylation but had no effect on PCB-mediated inhibition of EGFR
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phosphorylation. The positive and negative controls were used to establish phosphorylated EGFR’s
dynamic range. Media was removed by aspiration and the cells were washed with PBS. Cells were
lysed in modified radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris, 150 mM NaCL, 1 mM
EDTA/EGTA/b-glyceraphosphate/Na3VO4, and 1% Triton X-100) supplemented with protease and
phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO).

The human male hepatoma-derived (HepG2) cell line (male origin) obtained from American Type
Culture Collection (ATCC, Manassas, MD) were plated 3x105 cells per well in 12-well plates and
grown to confluence in DMEM High Glucose media (GE Healthcare, Pittsburgh, PA) supplemented
with 10% fetal bovine serum (FBS) and 1% antimycotic/antibiotic solution (Mediatech, Manassas,
VA). HepG2 cells were treated and collected in a similar manner as the AML-12 cells. The Aroclor
1260 concentration-dependence assay was conducted in AML-12s and HepG2s similarly to
aforementioned experiments with varied concentrations of Aroclor 1260 ranging from (0, 0.38, 0.94,
1.88, 5, 10, 15, 20 µg/mL) at constant EGF concentration. Aroclor 1254 was used at a concentration
of 20 µg/mL similarly to the Aroclor 1260 experiments in HepG2s. The experiments with individual
PCB congeners (PCB 3, PCB 6, PCB 8, PCB 9, PCB 138, PCB 149, PCB 151, PCB 153, PCB 170,
PCB 174, PCB 180, and PCB 187 were performed with HepG2 cells at congener concentrations of
10 µM.

Preparation of Expression vectors
A mCAR-active luciferase reporter containing two AGGTCA repeats separated by 4 base pairs was
generated as an expression construct for this receptor (36). Murine CAR cDNA was generously
provided by T.H Rushmore (Merck, Westpoint, PA). The expression vector used was a modified
version of pcDNA3.1 (Thermo Scientific, Waltham, MA) in which the CMV promoter was replaced
with a weaker promoter, the minimal promoter from the rat glutathione S-transferase A2 gene (58)
which produces lower expression levels of CAR.
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Transient Transfection Assays
HepG2 cells were plated in Nunc 24-well plates (Thermo Scientific, Waltham, MA) and transfected
at 40–60% confluence. Unless otherwise specified, the transfection mix per well contained 150 ng
β-galactosidase expression plasmid pCMV-β, (Stratagene, San Diego, CA) as a transfection
control, 50 ng receptor expression plasmid, and 150 ng luciferase reporter plasmid. All cells were
transfected using lipofectamine reagent (Thermo Scientific, Waltham, MA) according to the
manufacturer's instructions and Opti-MEM (Thermo Scientific, Waltham, MA) as the transfecting
medium. After a 4-hour incubation, the medium was changed to the growth media, DMEM (Thermo
Scientific, Waltham, MA) supplemented with 10% FBS and 1% antimycotic/antibiotic solution and
24 hours after transfection, cells were treated with either Aroclor 1260 (0-20 µg/mL), androstanol
(10 µM) or 1,4-Bis(3,5-dichloro-2-pyridyloxy)benzene (TCPOBOP, 10µM) either alone or in
combination. After another 24 hours the cells were harvested using cell lysis buffer (Promega,
Fitchburg, WI) and the β-galactosidase activity determined spectrophotometrically on a Biotek
Synergy plate reader using chlorophenol red b-D-galactopyranoside as substrate. The luciferase
activity was determined using a Berthold (Bad Wildbad, Germany) plate reading luminometer using
the luciferase assay kit from Promega, (Fitchburg, WI) according to the manufacturer’s instructions.
All data are presented as normalized luciferase activity/β-galactoside activity from 4 independent
experiments and all comparisons were made to the untreated group.

Exposure of mice to Aroclor 1260
The mouse liver samples used in this study were obtained from archived (-80°C) tissues obtained
during a previous study (3). The treatment protocol was approved by the University of Louisville
Institutional Animal Care and Use Committee. Male C57Bl/6J mice (8 weeks old; The Jackson
Laboratory, Bar Harbor, ME, USA) were divided into 4 study groups (n = 10) based on diet and
Aroclor 1260 exposure in this 12-week study utilizing a 2 × 2 design. Mice were fed either a control
diet (CD, 10.2% kCal from fat; TD.06416 Harlan Teklad, Indianapolis, IN) or a HFD (42% kCal from
fat; TD.88137 Harlan Teklad, Indianapolis, IN). Aroclor 1260 (AccuStandard, CT, USA) was
administered in corn oil by oral gavage (vs. corn oil alone) at a dose of 20 mg/kg early in week 1,
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at a dose similar to the maximum human PCB exposures seen in the Anniston cohort (10). Mice
were housed in a temperature- and light controlled-room (12 h light; 12 h dark) with food and water
ad libitum. The animals were euthanized at the end of week 12 using ketamine/xylazine, 100/20
mg/kg body weight, i.p., respectively), followed by exsanguination to minimize blood in the liver
sample. The mice fed a HFD and treated with Aroclor 1260 developed steatohepatitis as
demonstrated by CAE and H&E staining. Aroclor 1260 treatment was associated with induction of
Cyp2b10 consistent with Car activation (3).

Western Blot Analysis

Mouse liver samples and cell culture lysates were homogenized in RIPA Buffer (100 mg tissue/0.5
mL RIPA supplemented with protease, and phosphatase inhibitors 1 µl/mL, (Sigma-Aldrich, St.
Louis, MO). The protein concentration was determined by bicinchoninic acid protein assay (SigmaAldrich, St. Louis, MO). Protein (15 µg) was separated on 7.5% SDS Gel (BioRad, Hercules, CA),
transferred to polyvinylidene difluoride membranes and blocked in Phosphate Buffered Saline
(PBS), pH 7.5 containing 1% Tween 20 (PBS-T) and 5% fat free Milk for 1 hour at room
temperature. Membranes were incubated at 4° C overnight with primary antibody at 1:1000 dilution
in 5% bovine serum albumin in PBS-T, then washed 4 times with PBS-T for 5 minutes followed by
incubation with secondary antibody 1:2000 in 5% Milk in PBS-T (Cell Signaling Technology,
Danvers, MA). After 4 PBS-T washes the membranes were incubated with ECL (Thermo Scientific,
Waltham, MA) and luminescent signals were captured with BioRad Chemidoc Imaging System
(Hercules, CA). Western blot protein bands were quantified using BioRad Image Software. For
detection of phosphoproteins, the phospho-antibody blots were stripped for 15 minutes (Thermo
Scientific, Waltham, MA) then re-probed using primary antibody against total protein overnight in
5% FF Milk in PBS-T. For phospho-Akt detection in mouse liver, duplicate protein samples were
analyzed in parallel under identical conditions. One blot was probed for phosphoprotein and the
other total protein and then both were re-probed for the loading control b-actin. Then the
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quantitation of band density was normalized to b-actin and then to total protein. This strategy was
necessary due to the inability to strip the phospho antibodies for Akt.

Statistical Analysis
Western blot densitometry values were statistically analyzed using Graphpad Prism Version 6 for
Macintosh (San Diego, CA). The data are expressed as mean ± standard error of the mean. All in
vitro datasets were compared using one-way ANOVA. p<0.05 was considered statistically
significant. In vivo data sets were compared using two-way ANOVA and p<0.05 was considered
statistically significant. The concentration dependence curves and IC50 values were generated by
fitting data to a 4-parameter logistic equation using SigmaPlot (Systat Software Inc. San Jose, CA).
RESULTS
Aroclor 1260 did not counter the inhibitory effect of the direct CAR antagonist, androstanol,
in vitro. To establish whether PCBs can directly activate mCAR, HepG2 cells transfected with
mCAR and a DR4 luciferase reporter gene were incubated with varied concentrations of Aroclor
1260 (0-20 µg/mL) and compared to control HepG2 cells treated with direct mCAR agonist,
TCPOBOP with or without androstanol exposure, as shown in Figure 5. As anticipated, treatment
with 10 µM androstanol reduced luciferase activity by 45%. The CAR ligand, TCPOBOP did not
significantly increase luciferase expression above control, consistent with the concept that CAR is
constitutively active when over-expressed in HepG2 cells. TCPOBOP treatment did, however,
completely reverse the inhibitory effect of androstanol in TCPOBOP-treated cells; cells treated with
both TCPOBOP and androstanol had the same activity as TCPOBOP-treated cells alone.

In

contrast, Aroclor 1260-treated cells failed to show reversal of the inhibitory effects of androstanol
at any concentration of Aroclor 1260 tested (from 0-20 µg/mL). In fact, Aroclor 1260 exposure
decreased luciferase activity either itself or in combination with androstanol. Because the negative
androstanol effect was observed at even the highest concentrations of Aroclor 1260 exposure,
Aroclor 1260 cannot counter androstanol’s inhibition of CAR, therefore is unlikely to be a direct
murine CAR ligand. Direct binding assays are required to conclude that PCBs cannot directly bind
to murine CAR.
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Figure 5. Effects of Aroclor 1260 exposure on a DR4-luciferase reporter gene activity in
HepG2 cells transfected with an expression vector for murine CAR: Cells were grown and
after transfection with expression vector for mCAR and luciferase reporter DR4 luciferase treated
with either androstanol, TCPOBP, or increasing amounts of Aroclor 1260 (0-20 µg/mL).

The

results as presented represent an n = 4 separate experiments. A One-way ANOVA statistical test
was utilized to compare experimental data to non-treated cells. * = p < 0.05
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Aroclor 1260 exposure decreased murine hepatic EGFR phosphorylation in vitro.

To

determine if Aroclor 1260 exposure could cause an indirect activation of CAR, the phosphorylation
status of EGFR was examined in AML-12 cells, a murine cell line that expresses normal functioning
EGFR. EGFR has multiple tyrosine residues within the receptor tyrosine kinase (RTK) domain that
have specific downstream effects when autophosphorylated upon homo or heterodimerization.
EGFR phosphorylation status was measured at Y1173, Y1068, and Y845 due to their specific
downstream effects. Y1173 phosphorylation regulates Akt, Y1068 phosphorylation regulates
STAT3, cRaf, and ERK, while Y845 phosphorylation has been shown to regulate CAR (19). In
AML-12 cells, EGFR phosphorylation at Y1173 was diminished by co-exposure to EGF and Aroclor
1260 for 30 min (Figure 6a), relative to EGF alone. EGFR inhibitor also decreased phosphorylation
at Y1173. EGFR phosphorylation at Y1173 was decreased 48% by Aroclor 1260 and EGF coexposure as compared to EGF alone (p = 0.006) (EGF 0.87 ± 0.09 vs. A1260 0.45 ± 0.1), while
EGFR inhibitor in the presence of EGF caused a 45% reduction in EGFR (0.39±0.03%)
phosphorylation. Phosphorylation at Y1068 was also decreased with EGF and Aroclor 1260 coexposure as shown in Figure 6b. In a similar manner, Y1068 EGFR phosphorylation was decreased
45% with Aroclor 1260 and EGF co-exposure for 30 min as compared to EGF alone (p = 0.003)
(EGF 0.92 ± 0.04 vs. A1260 0.51 ± 0.08 vs. EGFR inhibitor 0.32 ± 0.02). Y845 phosphorylation
also decreased in AML-12 cells with Aroclor 1260 and EGF co-exposure (Figure 6c). At Y845,
EGFR phosphorylation was decreased 43% with Aroclor 1260 and EGF exposure as compared to
EGF alone (p = 0.005) (EGF 0.61 ± 0.05 vs. A1260 0.35 ± 0.03 vs. EGFR inhibitor 0.12 ± 0.02). In
the AML-12 cells, the concentration-dependence of the inhibition of EGFR Y1173 phosphorylation
by Aroclor 1260 is shown in Figure 6d. The IC50 value obtained was 1.2 ± 0.3 µg/mL and the Hill
slope coefficient is 1.4 ± 0.5 indicating one binding site at EGFR. These findings demonstrate that
not only can PCBs diminish EGFR phosphorylation contributing to increased CAR activity (Y845)
previously reported, but they may also affect many other downstream targets independent of CAR
(Y1068, Y1173) based on the decreased phosphorylation of the EGFR tyrosine residues and the
specific downstream targets.
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Figure 6.

Decreased EGFR phosphorylation at multiple sites in vitro with Aroclor 1260

exposure: AML-12 cells treated with EGF and either EGFR inhibitor (EI), or Aroclor 1260 (A1260)
for 30 minutes were lysed for western blot analysis as described in the Materials and Methods. A.
EGFR phosphorylation at Y1173 in AML-12 cells was decreased by Aroclor 1260 and EGF coexposure as compared to EGF alone (p = 0.006). B. EGFR phosphorylation at Y1068 was
decreased with Aroclor 1260 and EGF co-exposure as compared to EGF alone (p = 0.003). C.
EGFR phosphorylation at Y845 was decreased with Aroclor 1260 exposure as compared to EGF
alone (p = 0.005). D. Aroclor 1260 displayed an IC50 of 1.18 ± 0.32 µg/mL for EGFR hypophosphorylation in AML-12 cells. The Hill slope coefficient was 1.39 ± 0.5. A representative blot of
the effect was shown in each panel and the graph represents quantitation of normalized protein
relative to EGF alone. The results are presented as mean ± SEM and represent an n = 3
experiments. A One-way ANOVA statistical test was utilized to compare experimental data to the
positive control data (EGF exposure alone), p < 0.05 was considered significant. * p < 0.05, ** p <
0.01
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Aroclor 1260 exposure diminished murine hepatic EGFR phosphorylation in vivo.

To

validate the effect of Aroclor 1260 on hepatic EGFR phosphorylation, hepatic EGFR Y1173
phosphorylation was measured in liver tissue from mice exposed to 20 mg/kg Aroclor 1260 in a
diet-induced obesity model of our previous study (3). Mice were fed either a control diet which
contained 10.2% of its calories as fat or a high fat diet which contained 43% of its calories as fat
for 12 weeks and treated with Aroclor 1260 (20 mg/kg by gavage) or vehicle control early in week
1. Mice treated with Aroclor 1260 plus a high fat diet developed NASH (3). As shown in Figure 7,
Panel A,

Aroclor 1260 exposure resulted in a 43% and 48% decrease in hepatic EGFR

phosphorylation at Y1173 in the control diet (CD 0.67 ± 0.12 vs. CD+ 0.39 ± 0.08) and high-fat diet
(HFD 0.64 ± 0.12 vs. HFD+ 0.34 ± 0.1) groups, respectively (p = 0.02). In Figure 7, Panel B, Aroclor
1260 exposure resulted in a 60% and 41% decrease in hepatic EGFR phosphorylation at Y1068 in
the control diet (CD 0.48 ± 0.14 vs. CD+ 0.19 ± 0.05) and high-fat diet (HFD 0.36 ± 0.07 vs.
HFD+ 0.21 ± 0.06) groups respectively (p – 0.03). In Figure 7 Panel C, Aroclor 1260 exposure
resulted in a 46% and 49% decrease in hepatic EGFR phosphorylation at Y845 in the control diet
(CD 0.64 ± 0.16 vs. CD+ 0.35 ± 0.08) and high-fat diet (HFD 0.53 ± 0.16 vs. HFD+ 0.27 ± 0.02)
groups respectively (p = 0.04)
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Figure 7. Effects of Aroclor 1260 exposure on mouse hepatic EGFR phosphorylation: Mice
were treated with Aroclor 1260 and placed on either a control (10.2% fat) or high fat-diet (43% fat)
for 12 weeks. Aroclor 1260 (20 µg/kg) was administered per os early in week 1. Phosphorylation
was determined at Y1173, Y1068, and Y845 of EGFR by Western blot analysis as described in
Methods and Materials. 3a: Hepatic Y1173 EGFR phosphorylation was diminished in mice
independent of diet by Aroclor 1260 exposure (p = 0.015). 3b: EGFR phosphorylation at Y1068
was diminished in mice independent of diet with Aroclor 1260 exposure (p = 0.03). 3c: EGFR
phosphorylation at Y845 was diminished in mice independent of diet with Aroclor 1260 exposure
(p = 0.04). A Two-way ANOVA statistical test was utilized to determine significant variation due to
diet or Aroclor 1260 exposure. # denotes significance due to Aroclor 1260 exposure, p < 0.05.
Displayed is a representative blot of the effect and the graph is a representation of the densitometry
results from n = 5 mice in each group.
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Aroclor 1260 exposure decreased phosphorylation of the downstream effectors of hepatic
EGFR signaling, Akt and mTOR in vivo.

The EGFR-AKT-mTOR pathway regulates hepatic

regeneration and energy metabolism. Aroclor 1260 exposure was associated with decreased
hepatic Akt and mTOR phosphorylation, independent of diet as shown in Figure 8 Panels A & B. In
the control diet (CD 0.79 ± 0.11 vs. CD+ 0.32 ± 0.11) and high-fat diet (HFD 0.53 ± 0.1 vs. HFD+
0.23 ± 0.07) groups, there was a 60% and 57% decrease in Akt phosphorylation due to Aroclor
1260 exposure, respectively (p = 0.002). For mTOR phosphorylation, there was a 70% and 25%
decrease in the control diet (CD 0.65 ± 0.15 vs. CD+ 0.19 ± 0.05) and high-fat diet (HFD 0.6 ± 0.21
vs. HFD+ 0.45 ± 0.11) groups with Aroclor 1260 exposure, respectively (p = 0.04).
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Figure 8. Effects of Aroclor 1260 exposure to mice for 12 weeks on hepatic Akt and mTOR
phosphorylation: Mice were treated early in week 1 with Aroclor 1260 (20 µg/kg per os.) and
western blot analysis of mouse liver conducted as previously described in Figure 7 and Materials
and Methods. A. Hepatic Akt phosphorylation was diminished in mice with Aroclor 1260 exposure
independent of diet (p = 0.002). B. Hepatic mTOR phosphorylation was decreased in mice with
Aroclor 1260 exposure independent of diet (p = 0.04). A Two-way ANOVA statistical test was
utilized to determine significant variation due to diet or Aroclor 1260 exposure. # denotes
significance due to Aroclor 1260 exposure, p<0.05. A representative blot of the effect is displayed
in each panel and the graph is a representation of the results from n = 5 mice in each group.
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Aroclor 1260 exposure decreased hepatic protein expression of c-Raf and STAT3 while ERK
activity was reduced by high-fat diet in vivo. Hepatic protein expression of STAT3 and cRaf
were decreased in an Aroclor 1260-dependent manner as shown in Figure 9 Panels A & B,
respectively. STAT3 expression was decreased 84% and 66% with Aroclor 1260 exposure in the
control diet (CD 0.57 ± 0.18 vs. CD+ 0.09 ± 0.06) and high-fat diet (HFD 0.31 ± 0.06 vs. HFD+ 0.11
± 0.04) groups, respectively (p = 0.007). c-Raf expression is decreased 56% and 77% with Aroclor
1260 exposure in the control diet (CD 0.57 ± 0.18 vs. CD+ 0.09 ± 0.06) and high-fat diet (HFD 0.31
± 0.06 vs. HFD+ 0.11 ± 0.04) groups (p = 0.0014). Due to unanticipated low expression of STAT3
and cRaf with Aroclor 1260 exposure, it was not possible to evaluate potential differences in the
phosphorylation status of these proteins. ERK activity was decreased slightly in a high fat-diet
dependent manner as shown in Figure 9c. Mice fed a high fat diet had a 29% decrease in ERK
phosphorylation compared to the untreated group (CD 0.26 ± 0.08 vs. HFD 0.19 ± 0.05) and a 78%
decrease in ERK phosphorylation in the Aroclor 1260 treated group (CD+ 0.61 ± 0.24 vs. HFD+
0.13 ± 0.02) (p = 0.04). While ERK phosphorylation is increased with Aroclor 1260 exposure in the
control diet group, the increase did not attain statistical significance (p = 0.22). Quantitation for
ERK1 phosphorylation is shown but similar findings were demonstrated in the quantitation of ERK2
phosphorylation as well. In summary, hepatic c-Raf and STAT3 protein expression was decreased
in a PCB-dependent manner in vivo, while ERK activity was decreased in a high fat diet-dependent
manner.

26

Figure 9. Effects of PCB exposure and high fat-diet for 12 weeks on mouse hepatic protein
expression of downstream targets of EGFR and ERK activity: Mice were treated for 12 weeks
as described above and western blot analysis conducted as previously described in Materials and
Methods. 5a: STAT3 protein expression was decreased in an Aroclor 1260-dependent manner
independent of diet (p = 0.007). 5b: cRaf protein expression was decreased with Aroclor 1260
exposure independent of diet (p = 0.0014). 5c: Phosphorylated ERK was decreased in a high fat
diet-dependent manner (p = 0.04). A Two-way ANOVA statistical test was utilized to determine
significant variation due to diet or Aroclor 1260 exposure. # = significant effect of Aroclor 1260
exposure p<0.05, ## = significant effect of high fat diet p < 0.05. A representative blot of the effect
is displayed in each panel and the graph is a representation of the results from n=5 mice in each
group.
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Aroclor 1260 exposure decreased hepatic EGFR phosphorylation in a human in vitro model.
We previously demonstrated that PCBs directly activated hCAR2 and hCAR3 (36), however, this
does not exclude simultaneous indirect CAR activation through inhibition of EGFR signaling. In
HepG2 cells, EGFR phosphorylation at Y1173, Y1068, and Y845 all decreased with EGF and
Aroclor 1260 co-exposure for 30 min. as shown in Figure 10 Panels A-C. Y1173 phosphorylation
was decreased 61% with Aroclor 1260 and EGF co-exposure as compared to EGF alone (p = 0.01)
(EGF 0.67 ± 0.13 vs. A1260 0.26 ± 0.02); EGFR inhibitor also suppressed phosphorylation of EGFR
(0.12 ± 0.02). EGFR phosphorylation at Y1068 was decreased 38% with Aroclor 1260 and EGF
co-exposure as compared to EGF alone, (p = 0.04) (EGF 0.95 ± 0.05 vs. A1260 0.59 ± 0.18 vs.
EGFR inhibitor 0.13 ± 0.025). EGFR phosphorylation at Y845 was decreased 40% with Aroclor
1260 and EGF co-exposure as compared to EGF alone (p =0.005), (EGF 0.81 ± 0.07 vs. A1260
0.49 ± 0.04 vs. EGFR inhibitor 0.36 ± 0.06). The concentration-dependence of the inhibition of
EGFR phosphorylation at Y1173 is shown in Figure 10d. The IC50 value was 4.0 ± 1.5 µg/mL for
EGFR hypo-phosphorylation by Aroclor 1260. The Hill slope coefficient is 1.37 ± 0.6.
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Figure 10. Decreased EGFR phosphorylation at multiple tyrosines in HepG2 cells with
Aroclor 1260 exposure: HepG2 cells were grown, treated with EGF and either EGFR inhibitor (EI)
or Aroclor 1260 (A1260) for 30 min, and lysed for western blot analysis as described in the materials
and methods. A. EGFR phosphorylation at Y1173 was decreased by Aroclor 1260 and EGF coexposure as compared to EGF alone (p = 0.011). B EGFR phosphorylation at Y1068 was
decreased by Aroclor 1260 and EGF exposure as compared to EGF alone (p = 0.04). C. EGFR
phosphorylation at Y845 was decreased by Aroclor 1260 and EGF co-exposure as compared to
EGF alone (p = 0.005). D. the IC50 value for EGFR hypo-phosphorylation in HepG2 cells was 4.0 ±
1.5 µg/mL. The hill slope coefficient was 1.37 ± 0.6 indicative of one binding site. A representative
blot of the effect is shown in each panel and the graph represents the mean ± SEM for n = 3
experiments for Y068, Y845, and 6 experiments for Y1173. The IC50 value for Aroclor inhibition of
phosphorylation was determined from 3 experiments for Y1173. A One-way ANOVA statistical test
was used to compare experimental data to the positive control data. * p < 0.05, ** p < 0.01.
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Specific PCB congeners decreased hepatic EGFR phosphorylation in a human in vitro
model. Different PCB congeners in Aroclor 1260 had varied effects on EGFR phosphorylation in
HepG2 cells as shown in (Figure 11 A & B). The “non-dioxin like” PCBs 151, 153, 170, 180, and
the “dioxin-like” PCBs 3, 6, 8, 9, 126 reduced EGFR phosphorylation. The PCBs 138, 149, 187,
and 174 had no significant effect. With PCB 180 and EGF co-exposure for 30 min, EGFR
phosphorylation decreased 54% (p = 0.012) in contrast to EGF alone (EGF 0.95 ± 0.05 vs. PCB
180 0.43 ± 0.14 vs. negative EGF control 0.17 ± 0.1). PCB 170 exposure decreased EGFR
phosphorylation 51% (p = 0.027) (PCB 170 0.46 ± 0.12). PCB 153 decreased EGFR
phosphorylation 49% (p = 0.036) (PCB 153 0.49 ± 0.14). PCB 151 exposure decreased EGFR
phosphorylation 57%, (p = 0.016) (PCB 151 0.41 ± 0.12).

PCB 126 decreased EGFR

phosphorylation 68% (p = 0.004) (PCB 126 0.3 ± 0.01). PCB 3 decreased EGFR phosphorylation
50% (p= 0.0015) in contrast to EGF alone (EGF 0.9 ± 0.06 vs. PCB 3 0.48 ± 0.07 vs. negative
EGF control 0.16 ± 0.07). PCB 6 decreased EGFR phosphorylation 46% (p= 0.0032) (PCB 6 0.49
± 0.1). PCB 8 decreased EGFR phosphorylation 46% (p= 0.003) (PCB 8 0.48 ± 0.07). PCB 9
decreased EGFR phosphorylation 52% (p= 0.001) (PCB 9 0.43 ± 0.05).These results demonstrate
that treatment with individual PCBs found in Aroclor 1260 and some not found in the mixture (PCB
3, 9) all blunt EGFR Y1173 phosphorylation, suggesting that this may be a phenomenon caused
by many PCB congeners.
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Figure 11. PCB congeners 3, 6, 8, 9, 126, 151, 153, 170, and 180 elicit the greatest decrease
in EGFR phosphorylation in HepG2 cells: HepG2 cells were treated with EGF and various PCB
congeners for 30 min, and subsequently lysed for western blot analysis as described in the
materials and methods. A. Co-exposure with PCB 180 and EGF decreased EGFR phosphorylation
at Y1173 as compared to EGF alone (p = 0.02), PCB 170 (p = 0.03), PCB 153 (p = 0.04), PCB 151
(p = 0.016), PCB 126 (p = 0.004). A representative blot representation of the results of the effect is
shown with the graph. The results are presented as mean ± SEM and represent the average
intensities from 3 experiments. B. Co-exposure with PCB 3 and EGF decreased EGFR
phosphorylation at Y1173 as compared to EGF alone (p = 0.0015), PCB 6 (p = 0.0032), PCB 8 (p
= 0.003), and PCB 9 (p = 0.001). C. Table comparing PCB congeners characteristics and EGFR
hypo-phosphorylation percentage as compared to EGF alone control. CP denotes co-planar; NCP;
non-co-planar. A One-way ANOVA statistical test was utilized to compare experimental data to the
positive control data * p <0.05, ** p < 0.01.
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Figure 12. Proposed PCB-mediated EGFR hypo-phosphorylation Model: Figure 12 represents
the hypothesis that PCBs bind to EGFR preventing EGF binding, thereby preventing
phosphorylation. Decreased EGF binding to EGFR leads to decreased Akt and mTOR
phosphorylation downstream of EGFR. STAT3, cRaf, and ERK are downstream targets of EGFR.
Chronic hypo-phosphorylation of STAT3 and cRaf leads to diminished expression either through
transcription regulation or protein ubiquitination. ERK activity was decreased on a high fat diet.
Phenobarbital was recently found to activate CAR through EGFR-RACK1 and PP2A (19) and
Aroclor 1260 acts in a similar manner leading to increased xenobiotic metabolism. HFD denotes
high fat diet; Ind denotes independent.
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DISCUSSION
In this study, Aroclor 1260 exposure did not counter androstanol’s inhibitory effect on
activation of mCAR in transient transfection assays. Unlike humans, mice do not express multiple
splice variants of CAR but rather produce a single transcript (59). Humans express at least three
splice variants, and we have previously shown that only some of these splice variants (CAR2 and
CAR3) were directly activated by PCB congeners in cell-based assays (36). Murine CAR is
homologous to human CAR1, which apparently is not directly activated by PCBs in cell-based
transactivation assays (36). Thus, PCB-induced mCAR activation must occur solely by indirect
mechanisms. Furthermore, the concept that PCBs act as indirect CAR activators would explain
how PCBs elicit a CAR activation response in vivo but cannot lessen androstanol’s inhibitory effect
in vitro. This may explain why PCBs worsened NAFLD in mice (18), while the direct CAR activator,
TCPOBOP, improved NAFLD in a diet-induced obesity co-exposure animal model (60).

To study the effects of PCBs on EGFR phosphorylation, I modeled our experimental design
on Negishi’s approach to investigate mechanisms of phenobarbital-induced indirect CAR activation
(19). In that study, EGFR phosphorylation was maximal 30 minutes after EGF treatment in vitro,
and phenobarbital inhibited EGF binding leading to downstream CAR activation. Likewise, I
determined the effects of PCBs by adding EGF and either EGFR inhibitor or PCB co-treatments.
EGFR phosphorylation was determined 30 minutes post-exposure in mouse and human
hepatocyte in vitro models as I found this time was optimum to induce robust EGFR
phosphorylation similarly to Negishi’s findings. Aroclor 1260 and specific PCBs including the
classically described ‘phenobarbital-like’ congener, PCB 153, reduced EGFR phosphorylation just
like phenobarbital (19). The 30-minute time course and the Hill slopes for the concentration
dependence curves were consistent with PCBs being simple EGFR antagonists, again similar to
phenobarbital (19). It is important to note that human PCB poisonings from the Yucheng incident
were previously linked to decreased placental EGF-stimulated EGFR phosphorylation and low birth
weights associated with exposures to PCBs 153 and 170 (33). Preliminary radiolabeled EGF
binding kinetic studies indicated possible competition for a low affinity EGF binding site in PCB-
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exposed Yucheng vs. unexposed placentas (33). Also, within the Yucheng cohort there is a
substantial increase in the mortality due to chronic liver disease and diabetes in both the 13 and
30 year follow up (12, 14). These proof of concept data document the potential human relevance
of our findings.

The IC50 for PCB-mediated EGFR Y1173 hypophosphorylation occurred at 1.2±0.3 µg/ml
in the murine AML-12 cell line and 3.9±1.9 µg/mL in the human derived HepG2 cell line. These
PCB concentrations were similar to those that directly activated hCAR2 and hCAR3 as determined
by a luciferase reporter construct in transient transfection assays (36). These exposures were also
similar to the hepatic PCB levels achieved when rodents were exposed to PCB 153 at an
environmentally relevant cumulative dose of 20 mg/kg (3.7 µg/g) (61). However, because PCBs
are lipophilic, they may concentrate in a cultured cell monolayer leading to significantly higher
cellular PCB concentrations than in the surrounding media. Because AML-12 cells were 3.25-fold
more sensitive to EGFR inhibition by PCBs than HepG2 cells, it is also possible that PCBs are
stronger indirect CAR activators in mice than in humans. In the 12-week mouse study, Aroclor 1260
(20 mg/kg) robustly induced Cyp2b10 in mice fed control diet (1000-fold) but was a much weaker
inducer of Cyp2b10 in mice fed a high fat diet (4-fold) (3). However, basal expression of Cyp2b10
was increased in livers of mice fed high fat diet. Our results show that the decrease in EGFR
phosphorylation associated with Aroclor 1260 treatment was not diet-dependent, and other factors
must regulate the basal and inducible CAR expression in the mouse liver. However, the in vivo
EGFR phosphorylation results are consistent with the in vitro findings. While PCBs appear to
simultaneously activate hCAR by both direct and indirect mechanisms; PCBs activate mCAR only
indirectly. To fully characterize the observed EGFR inhibition, ligand-binding studies with PCB
congeners and the extracellular domain of EGFR should be performed in the future.

In cell culture experiments, reduction of EGFR phosphorylation occurred with Aroclor 1260,
the dioxin-like congener, PCB 126, and the non-dioxin-like PCB congeners 151, 153, 170 and 180.
While all the PCB congeners tested diminished EGFR phosphorylation, the most significant were
among the higher chlorinated, non-coplanar congeners tested. The congener specific effect on
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EGFR phosphorylation is most likely due to the differences in binding affinity between these
congeners to EGFR which will be evaluated in future studies. PCBs have similar structures to
phenobarbital which may explain their similar modes of action through EGFR. While Aroclor 1260
also reduced EGFR phosphorylation in vivo, it did not increase expression of Cyp1a2 (3),
suggesting that AhR was not activated at the level of Aroclor exposure in this model. While the
related persistent organic pollutant, 2,3,7,8-tetrachlorodibenzodioxin (TCDD), reduced EGFR
phosphorylation in an AhR-dependent manner (62), this process required 12-14 hours to reach
maximal effect in vitro. In contrast, our cell culture experiments employed a shorter 30-minute
study, making a receptor-dependent transcriptional response unlikely. These, and other data, (19,
33) suggest that AhR activation is not required to reduce EGFR phosphorylation. However, this
does not exclude the possibility that AhR-dependent pathways could also exist for PCBs, as they
do for TCDD. In fact, among tested PCB congeners, the strongest observed effect occurred for
PCB 126, a potent AhR activator. Previously PCB 104 was shown to activate EGFR demonstrating
that there are varied effects on EGFR based on the congener used (63). Also PCB 104 is not
present in Aroclor 1260 and was not used due to only being detected in the serum of 1 of 26
industrial workers (64).

Loss of EGFR activity has been implicated in both the progression of liver disease and
diabetes (25, 52). 39.6% of chemotherapy patients on gefitinib, a small molecule EGFR inhibitor,
developed abnormal liver function (65). In humans and mice loss of EGFR function has been
implicated in the development of steatosis (30, 54). EGFR is hepatoprotective against chemicalinduced liver injury and EGF supplementation attenuated alcohol-induced liver disease (31, 32).
Loss of EGFR function has also been implicated in diabetes as it diminishes insulin production,
islet cell mass, and proliferation (52, 53). Together these studies and our findings suggest that
future studies should be performed to elucidate the potential role of PCB-induced EGFR inhibition
in NAFLD and diabetes. In addition to EGFR, activity of downstream targets including the
PI3K/AKT/mTOR pathway were diminished as well. Decreased PI3K/AKT/mTOR signaling was
also associated with type-II diabetes (66) and increased gluconeogenesis, a common feature in
NASH. Our results show that PCB exposure decreased Akt and mTOR phosphorylation which is
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consistent with the observation that EGFR is directly involved in PI3K phosphorylation, independent
of insulin receptor signaling. The diabetes and steatohepatitis associated with Aroclor 1260-HFD
co-exposures were recently characterized in mice (18). mTOR is an energy sensor kinase that is
critical in regulating hepatic energy homeostasis. PI3K/Akt have been recently implicated in lipid
efflux in the development of steatosis (67). It now appears possible that alterations in the Akt/mTOR
pathway, independent of CAR and PXR, may contribute to the abnormal hepatic glucose and lipid
metabolism associated with steatohepatitis, and this mechanism requires further investigation.

STAT3 and cRaf are other downstream targets of EGFR that were impacted by PCB
treatments in the animal model.

The phosphorylation status of these targets could not be

determined as their expression was decreased significantly by PCBs through yet unknown
mechanisms. STAT3, a critical second messenger in interleukin 6 and leptin signaling, also
regulates hepatic intermediary metabolism and the mitogenic response during liver regeneration.
The STAT3 pathway is activated in human NAFLD and worsens insulin resistance while protecting
against lipotoxicity by increasing autophagy and decreasing endoplasmic stress (68). STAT3
polymorphisms have been associated with human NAFLD (69). In our HFD-fed mice, Aroclor 1260
increased interleukin 6, while leptin was increased regardless of PCB exposure (3). However,
decreased STAT3 levels may have induced adipocytokine resistance due to disrupted intracellular
signaling. This warrants further study because IL-6 deficient mice fed HFD displayed worsened
NASH (70), while leptin resistance is implicated in the pathogenesis of obesity and metabolic
syndrome.

While cRaf protein levels were reduced by PCB exposure, phosphorylation of its
downstream target, ERK, was reduced by HFD. This is a novel nutrient-toxicant interaction. In the
literature, this pathway has been linked to liver regeneration and carcinogenesis, but more recently
it has been found to regulate lipid metabolism through sterol regulatory element binding protein-1
(SREBP-1) phosphorylation (71). PCBs have been demonstrated to induce oxidative stress in rats
and ERK activity is increased in response to oxidative stress (72, 73). I demonstrate that hepatic
ERK activity is diminished on a HFD demonstrating that with PCB exposure and a HFD, the liver
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cannot properly respond to oxidative stress potentially promoting steatohepatitis. In rats exposed
to high dose of PCB 153 for 5 days, Akt and ERK activity increased which is characteristic of
hepatocellular carcinoma (74), while with a low exposure to Aroclor 1260 in mice for 12 weeks, I
observed decreased Akt activity. More research is required to understand the possible congener
dose, time and species-specific responses of Akt, mTOR, and ERK to PCB treatments.
Furthermore, while I identified new pathways beyond hepatic nuclear receptors by which PCBs can
impact hepatic cell signaling, future studies are required to demonstrate if PCB-mediated EGFR
inhibition promotes NAFLD and diabetes. Likewise, the precise mechanism by which PCBs inhibit
EGFR activation requires elucidation which are a part of future studies ongoing in our laboratory.

In conclusion, polychlorinated biphenyls diminish epidermal growth factor receptor
signaling in both humans and mice, leading to dysregulation of critical effector kinases and
transcription factors implicated in hepatic xenobiotic, glucose, and lipid metabolism (Figure 12).
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CHAPTER 3

EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING DISRUPTION BY ENDOCRINE
AND METABOLIC DISRUPTING CHEMICALS

INTRODUCTION

Exposures to environmental chemicals occurs primarily through oral, inhalation, and
transdermal routes. Subsets of chemicals or their metabolites bio-accumulate as demonstrated
from population-based studies (10, 75, 76). Endocrine and metabolic disrupting chemicals
(EDCs/MDCs) include pesticides, herbicides, dioxins, and poly-chlorinated biphenyls (PCBs) (10,
77-80). EDCs disrupt hormonal and growth factor signaling thus contributing to adverse outcomes
in sex organs and metabolic organs. These metabolic aberrations due to chemical exposures are
concerning due to the inexplicable rising rates of metabolic disorders (80). These classes of
chemicals have been linked to many adverse outcomes such as hepatotoxicity, skin rash,
developmental disorders, pancreatic dysfunction, and diabetes in humans and animal models (7,
78, 81-86). Recently chemical exposures have been found to promote a distinct type of fatty liver
disease termed toxicant associated fatty liver disease (TAFLD) (5, 87, 88). TAFLD is perhaps the
newest disease associated with EDC/MDC exposures (80).
The Environmental Protection Agency (EPA) has established the ToxCastDB database to
prioritize, screen, and catalog high-priority chemicals using high throughput receptor activation
assays in part to address issues of endocrine disruption (89). The ten EDCs/MDCs included in the
ToxCastDB

characterized

in

this

study

include

atrazine,

alachlor,

lindane,

dieldrin,

dichlorodiphenylchloroethane (DDT), dichlorodiphenyldichloroethylene (DDE), trans-nonachlor,
chlordane, PCB-153, and PCB-126. These chemicals have previously been characterized as
inducers of constitutive androstane receptor (CAR) dependent gene expression (9, 22, 90-92).
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These pesticides, herbicides, and PCBs all overlap in their abilities to activate CAR-dependent
gene expression, while also exerting adverse effects primarily in the liver, pancreas, , and
development (21, 93-95). Cyp2b10 induction is an indicator of constitutive androstane receptor
(CAR) activation. Direct CAR activation has been shown to be hepatoprotective in NAFLD animal
models (16, 17, 60). Recent investigation of CAR activation has elucidated indirect activation by
xenobiotics through epidermal growth factor receptor (EGFR) inhibition leading to CAR
dephosphorylation and thus activation (19, 96). If the mode of action for environmental chemicals
is indirect through EGFR inhibition, multiple signaling pathways would be disrupted potentially
countering the protective effects of CAR activation as seen with direct ligand activation (16, 17).
These observations add to the complexity of how these compounds elicit their effects while
providing some explanation as to why they are hepatotoxic. If these compounds act through EGFR
inhibition, this could disrupt a vast signaling cascade essential for hepatic function (25, 28, 30, 31,
54, 96, 97).
Dermal rashes upon exposure to pharmaceutical EGFR inhibitors, dioxins, PCBs,
chlorinated pesticides and herbicides are well-documented adverse effects common between
these classes of compounds (83-86, 94, 103-108). Loss of EGFR function in mice leads to skin
inflammation suggesting the importance of EGFR function for skin homeostasis and wound healing
(105, 106, 109, 110). PCB exposure in pregnant women has been shown to diminish placental
EGFR phosphorylation which correlated with lower birth weights (33). EGFR is instrumental in
development and homozygous EGFR-null mice do not survive past postnatal day 20 (majority die
on postnatal day 1) and have severe abnormalities (111-113). These previous studies serve to
illustrate the multiple adverse effects due to inhibition of EGFR signaling in the liver, b-islets of the
pancreas, skin, and during development. With the literature demonstrating that the selected
EDCs/MDCs are CAR activators, their mode of action has not been firmly established. Therefore,
compounds in this study were investigated to determine if they directly activate CAR or act through
EGFR inhibition. Should the selected pollutants inhibit EGFR function at environmentally relevant
concentrations, then the impact of their signaling disruption on human health and disease could be
evaluated in future studies.
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MATERIALS AND METHODS
Compound Selection:
A set of 10 MDCs/EDCs known to activate CAR were selected from high priority chemicals
identified in NHANES or ToxCastDB. These chemicals included trans-nonachlor, chlordane, DDE,
DDT, dieldrin, alachlor, atrazine, lindane, PCB-153, and PCB-126. Trans-nonachlor and DDE were
purchased from SUPELCO (Bellefonte, PA). Lindane and DDT were purchased from CHEM
Service (West Chester, PA). Dieldrin, chlordane, atrazine and alachlor were purchased from Sigma
Aldrich (St. Louis, MO). PCB-153, a non-dioxin like PCB (NDL) and PCB-126, a dioxin-like PCB
(DL PCB) were purchased from AccuStandard (New Haven, CT).

Plasmid construction:
mCAR cDNA was a generous gift from Tom Rushmore (Merck Research Laboratories, West Point,
PA) which was subcloned into a modified version of pGL3-basic (58, 96). Mice lack CAR splice
variants found in humans but the mCAR is 89% homologous to hCAR1. Restriction endonucleases
and T4 DNA ligase were purchased from New England BioLabs (Ipswich, MA). Dimethyl sulfoxide
(DMSO) was purchased from Fisher BioReagents (Thermo Fisher Scientific, Pittsburg, PA).
Lipofectamine and Opti-MEM were acquired from Life Technologies Inc. (Carlsbad, CA).
Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).

Cell culture:
A-431 Cells: The human epidermoid carcinoma cell line derived from a female patient was obtained
from American Type Culture Collection (ATCC, Manassas, MD). Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (VWR, Radnor, PA) supplemented with 10% fetal bovine serum
and 1% antimycotic/antibiotic solution (Mediatech, Manassas, VA). The cells were incubated in a
5% carbon dioxide atmosphere and 95% humidity at 37° and sub-cultured every 2 days. HepG2
cells were used as previously described in chapter 2.
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Transfection:
HepG2 cells were plated in Thermo Scientific Nunc 24-well plates and transfected at 40-60%
confluency. The transfection mix per well contained 150 ng β-galactosidase expression plasmid
(pCMV-β, Stratagene, CA) as a transfection control, 50 ng receptor expression plasmid (pGL3mCAR), and 150 ng reporter plasmid (pGL3-DR4-Luc) if not otherwise specified. The artificial
DR4 construct consists of two AGGCTA repeats separated by 4 base pairs and has been
described previously (36, 96). All cells were co-transfected by lipofection using Lipofectamine
reagent according to the manufacturer’s instructions (Thermo-Scientific, Waltham, MA) and OptiMEM (reduced serum medium) was used for the transfection medium. After 4 hours of incubation,
the medium was changed to DMEM supplemented with 10% FBS and 1% antimycotic/antibiotic
solution and cells were left overnight to recover. Compounds of interest were then added to the
cells and incubated for 24 hours. DMSO was used as a vehicle for all compounds (final
concentration 0.1%). 1,4-Bis-[2-(3,5-dichloropyridyloxy)] benzene, 3,3′,5,5′-Tetrachloro-1,4bis(pyridyloxy)benzene (TCPOBOP) (Sigma-Aldrich, St Louis MO) was used as a positive control
as it is a murine CAR direct agonist.

Luciferase Reporter assay:
Cells were washed twice with phosphate buffered saline (PBS 1X), harvested using 50 µL cell lysis
buffer (Promega, Madison, WI) and subjected to a single freeze-thaw event. For β-galactosidase
assays, cell extracts (5 µL), were incubated with chlorophenol red β-galactopyranoside (CPRG,
Sigma-Aldrich, St Louis MO) at 37°C for 30-60 minutes. The enzyme activity was measured
spectrophotometrically at 595 nm using the Bio-Tek Synergy HT multi-mode micro plate reader.
Luciferase activity assays were performed on cell extracts (5 µL) using the Luciferase Assay
System (Promega, Madison, WI). Luminescence was measured using the Orion L micro plate
luminometer (Berthold Detection Systems, Pforzheim, Germany) over a 10 second period.
Receptor activation was measured by luciferase activity and results were normalized to the amount
of β-galactosidase expressed.
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EGF Assay in HepG2 cells:
Cells were pre-treated with 10 µM (this concentration was found to not be cytotoxic in MTT assays,
(Figure 37, Appendix I) (or 4.1µg/mL for the chlordane mixture) of the compound of interest for 10
minutes followed by 30 minutes with 20 ng/mL of epidermal growth factor (EGF) (Fisher Scientific,
Pittsburgh, PA). EGF alone for 30 minutes was used as a positive control, and 30-minute treatment
with 0.1% DMSO was used as a negative control. The 30-minute treatment was used as that was
the peak time for EGFR phosphorylation (96). The positive and negative controls were used to
establish phosphorylated EGFR’s dynamic range. Media was removed by aspiration and the cells
were washed with PBS. Cells were lysed in modified radioimmunoprecipitation assay (RIPA) buffer
(20 mM Tris, 150 mM NaCl, 1 mM EDTA/EGTA/b-glycerophosphate/Na3VO4, and 1% Triton X-100)
supplemented with protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO).

EGF Endocytosis Assay in A-431 Cells:
This assay was modified from a previously described method (114). A-431 cells were used as they
express 2.6 ´106 epidermal growth factor receptors per cell (115). Alexa Fluor 555 labeled EGF
was purchased from Thermo Scientific, (Philadelphia, PA) and was used at 20 ng/100 µL. After a
3-hour serum starvation, A-431 cells were exposed to varying concentrations of the compounds
(10-19 -10-3 M) for 10 minutes. Since chlordane is a mixture it was administered at the following
concentrations 0.41x10-16 to 41 µg/100µL. The chlordane competition curve is in the logarithmic
scale for ease of comparison. Positive control cells were treated with 0.1% DMSO and negative
control cells were treated with 20 ng/100 µL of unlabeled EGF purchased from Millipore (Norwood,
OH). This served as a negative since the EGF receptors would be saturated and endocytosed
preventing fluorescently labeled EGF from binding thus preventing any signal. Cells were then
treated with 20 ng/100µL of Alexa Fluor 555 labeled EGF for 30 minutes. This was followed by 3
washes with pre-warmed PBS and incubation with 3.7% formaldehyde for 15 minutes. Cell nuclei
were then stained with Hoechst 33342 purchased from Thermo Scientific (Philadelphia, PA) at 1
µg/100 µL for 15 minutes. Images and data were obtained via an ArrayScan HCS 4.0 Reader. Filter
sets specific for Hoechst labeled nuclei and the Alexa Fluor 555-EGF were used for detection. A
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20X microscope objective was used for imaging and the SpotDetector bioapplication was used to
acquire and analyze images. Approximately 500 cells from randomized fields were analyzed for
each well. The equation used to normalize 555-EGF count/nuclei values is listed below.

9:;<=>?@
C ∗ 100
𝐴𝑙𝑒𝑥𝑎 𝐹𝑙𝑢𝑜𝑟 555 𝐸𝐺𝐹 𝐸𝑛𝑑𝑜𝑐𝑦𝑡𝑜𝑠𝑖𝑠 = 61 − 9AB<=>?@

To determine if these compounds could displace 555-EGF from the ligand binding domain of EGFR
cells were pre-treated with 20 ng/100µL of Alexa Fluor 555-EGF for 2.5 minutes on ice to prevent
endocytosis. Cells were then exposed to 1pM of (PCB-126, PCB-153, trans-nonachlor) 0.041
pg/100µL of chlordane and 100 pM of atrazine for 2.5 minutes on ice. The plated cells were
incubated at 37° C for 25 minutes and the assay was continued as previously described. The
relative effect potencies (REPs) were calculated from the normalized IC50 values from the EGF
endocytosis assay for the compounds tested (normalized to trans-nonachlor, most potent).

Western Blot Analysis:
Cell culture lysates from HepG2 and A-431 cells were homogenized in RIPA Buffer (150 µL RIPA
supplemented with protease, and phosphatase inhibitors 10 µL/mL, (Sigma-Aldrich, St. Louis, MO).
The antibodies for p-EGFR Y1173 were obtained from Abcam (Cambridge, MA). The antibody for
EGFR was purchased from Santa Cruz (Santa Cruz, CA). Antibodies for p-ERK1/2 and ERK1/2
were purchased from Cell Signaling Technology (Danvers, MA). Full methods for western blot
analysis can be found in chapter 2.

Molecular Modeling and Docking Simulation:
The inactive EGFR structure (INQL) and select chemicals from PubChem were prepared using
Chimera (116-118). Docking simulations were conducted using AutoDock Vina and the predicted
sites with the best scores were further analyzed. The top two ligand positions were selected based
on their root-mean-square deviation (RMSD) lower and upper bound metrics. The EGFR tyrosine
kinase structure (4HJO) was used for docking simulations for atrazine (119). The structures for the
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ligands were obtained from PubChem; PCB-153 (CID:37034), PCB-126 (CID: 63090), transnonachlor (CID: 19520), atrazine (CID: 2256) (117).

NHANES 1999-2004 and Population Analysis
University of Louisville Institutional Review Board determined that the use of the publicly available
de-identified 1999-2004 NHANES data (64) was not considered human subjects research and did
not require IRB approval. The methods used to acquire NHANES samples and determine the
chemical concentrations were described previously (64). The NHANES (1999-2004) wet weight
and lipid adjusted means of trans-nonachlor, PCB-153, and PCB-126 were used to for comparison
with the calculated IC50 values.

Statistical analysis
All statistical analyses were performed using GraphPad Prism version 7 for Macintosh (GraphPad
Software Inc., La Jolla, CA, USA). Data are expressed as mean ± SEM. Multiple group data were
compared using One Way ANOVA followed by Bonferroni's post-hoc test for parametric data for all
pairwise comparisons. P <0.05 was considered statistically significant. Competitive binding curves
and IC50 values were calculated with Graphpad Prism 7 using two sites – Fit logIC50. Two group
comparisons were made using a two-tailed unpaired t-test and a P<0.05 was considered
statistically significant.

RESULTS
Selected compounds do not appear to be direct agonists of CAR, but trans-nonachlor,
chlordane and atrazine inhibit EGF stimulated Y1173 phosphorylation of EGFR
To determine whether previously characterized CAR activators were direct CAR activators, a DR4luciferase reporter in HepG2 cells co-transfected with mCAR was used. The assay was performed
for the following compounds: atrazine, dieldrin, trans-nonachlor, lindane, alachlor, chlordane, DDT
and DDE, at 10 µM to evaluate their ability to directly activate CAR. PCB-126 and PCB-153 were
not used for this assay as the results have already been published and both were found to ablate
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EGF-mediated EGFR phosphorylation (96). If the compounds act as direct activators of mCAR then
they should increase luciferase activity similarly to TCPOBOP (Fig. 9a). As anticipated, TCPOBOP
increased reporter signal by 2.6-fold, which is in good agreement with our previous work and others
(96, 120). None of the compounds significantly increased the reporter expression even though in
vivo studies demonstrate that they induce Cyp2b10.

CAR has been shown to be indirectly activated through inhibition of EGFR signaling (19). In Fig.
9b compounds that can prevent EGF stimulation of EGFR in HepG2 cells were identified. The EGF
assay in HepG2 cells was performed with the same chemicals previously used at 10 µM
concentration for 10 minutes followed by EGF at 20 ng/mL for 30 minutes. Compared to EGF alone,
atrazine, chlordane, and trans-nonachlor all substantially diminished EGF stimulation of EGFR
phosphorylation: 73% for atrazine (p<0.02) and 82% for trans-nonachlor (p<0.01) and chlordane
(p<0.01). DDE, DDT, dieldrin, alachlor, or lindane did not significantly alter EGFR phosphorylation
in the presence of EGF (Fig. 9b). Indirect CAR activation by these compounds may occur through
uncharacterized EGFR-independent mechanisms. These experiments suggested that chlordane,
trans-nonachlor, and atrazine were indirect CAR activators possibly acting through EGFR
inhibition. Chlordane, trans-nonachlor, and atrazine were chosen to investigate further along with
previously characterized EGFR signaling disruptors PCB-126 and PCB-153 (96)
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Figure 13. Selected compounds do not appear to be direct agonists of CAR, but transnonachlor, chlordane and atrazine inhibit EGF stimulated Y1173 phosphorylation of EGFR:
A. HepG2 cells were co-transfected with pCMVβ, mCAR and pGL3-DR4-Luc constructs and
exposed to each compound at 10 µM, 0.1 % DMSO was used as a negative control, and TCPOBOP
(direct mCAR agonist) was used as positive control. The data are presented as mean ± SEM and
a n = 4 was used, A * denotes a P<0.05. B. HepG2 cells were pre-exposed to the select compounds
at 10 µM for 10 minutes before EGF administration at 20 ng/mL for the experimental groups for 30
minutes. 0.1% DMSO and EGF treated cells served as the negative and positive controls,
respectively. EGFR phosphorylation at Y1173 was measured via western blot analysis and was
normalized to total EGFR. An n = 4 was used and the values are represented as mean ± SEM for
Fig 13a-b. Experimental values were compared to EGF alone values by a one-way ANOVA for Fig
13b. A * denotes a P<0.05, and **** denotes a P<0.0001 and are considered statistically significant.
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Trans-nonachlor, chlordane, PCB 126, PCB-153, and atrazine prevent EGF endocytosis in
A-431 cells
To determine whether select compounds prevent EGF endocytosis, a competition assay in human
A-431 cells using Alexa Fluor 555-EGF (20 ng/100 µL or 32 nM) and increasing concentrations of
the select compounds and non-labeled EGF (10-19 - 10-3 M) was conducted. Fluorescently labeled
EGF in the absence of an inhibiting compound will bind the EGFR leading to dimerization and
endocytosis. The amount of fluorescent signal per cell is a measure of EGF-EGFR endocytosis,
and EGF binding in the presence of varied concentrations of these compounds. If fluorescently
labeled EGF is incapable of binding the EGFR, there will be no to low fluorescent signal per cell
indicating a lack of EGF binding and / or dimerization and endocytosis. This concentration of Alexa
Fluor 555-EGF was used as it was previously shown to give robust signal in the Cellomics assay
(114). The EGFR has two conformational states that have different affinities for EGF (33, 121, 122).
The lower affinity state is most likely the unliganded monomer, while the high affinity state is
probably unliganded, pre-formed dimers and/or tetramers (122, 123). Thus, the biphasic
competition curves likely reflect these two affinity states where the first IC50 value is the low affinity
state (EGFR monomer) and the second IC50 is the high affinity state (pre-formed EGFR dimers or
tetramers) of the EGFR. Figure 14a shows non-labeled EGF’s ability in preventing fluorescent EGF
endocytosis and EGF’s IC50 value was log -15.4 ± 0.31 M for the high affinity site and log -8.99 ±
0.6 M for the low affinity site. Fig 14b shows that the IC50 value for prevention of EGF endocytosis
by chlordane was log -16.49 ± 0.33 M (0.0013 fg/100µL) for the high affinity site and log -4.0 ± 0.54
M (4.1 µg/100 µL) for the low affinity site. Fig 14c shows the IC50 value for loss of EGF endocytosis
due to trans-nonachlor of log -16.6 ± 0.23 M for the high affinity site and log -3.88 ± 0.72 M for the
low affinity site. Fig 14d shows IC50 values for loss of EGF endocytosis due to PCB-126 to be log 16.07 ± 0.31 M for the high affinity site and log -8.38 ± 0.24 M for the low affinity site. Fig 14e shows
the IC50 values for PCB 153 of the loss of EGF endocytosis being log -12.4 ± 0.2 M for the high
affinity site and log -5.26 ± 0.49 M for the low affinity site. Atrazine’s IC50 value for loss of EGF
endocytosis was log -10.42 ± 0.34 M for the high affinity site and log -3.51 ± 0.95 M for the low
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affinity site (Fig 14f). These findings suggest that chlordane, trans-nonachlor, PCB-126, PCB-153,
and atrazine are potent EGFR antagonists that prevent EGF endocytosis.
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Figure 14. Chlordane, trans-nonachlor, PCB-126, PCB-153, and atrazine prevent EGF
endocytosis in A-431 cells: A-G. A-431 cells were serum starved for 3 hours before pre-treating
cells for 10 minutes with varying concentrations of the select compounds. Cells were then treated
with 20 ng/100 µL of Alexa Fluor 555 conjugated EGF for 30 minutes. Fluorescent EGF spots per
stained cell nuclei were the measure for this assay. 0.1% DMSO pre-treated cells served as the
positive control, and cells pre-treated with 20 ng/100µL of unlabeled EGF served as the negative
control for this experiment. An n = 3 (3 96-well plates) was used and there were 8 technical
replicates for each concentration for each individual plate. Values were normalized between the
positive and negative controls of the plate with the equation described in methods. Curves were
fitted by nonlinear regression with GraphPad 7 Prism software and a two site logIC50 curve fit for
the data for the potent compounds and non-labeled EGF.
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Relative effect potencies and NHANES serum concentrations for trans-nonachlor, PCB-126,
and PCB-153
In this study, the data gathered was used to develop relative effect potencies (REPs) for EGFR
inhibiting compounds. REPs are used to rank chemicals based on their potency to activate or inhibit
a receptor and in turn that value is used for risk assessment based on the individual’s additive body
burden of multiple chemicals. (Table 1) REPs were calculated by normalizing the high affinity site
IC50 values to the most potent trans-nonachlor. In descending order of REP values Trans-nonachlor
had a REP of 1, PCB-126 had a REP of 0.33, PCB-153 had a REP of 8.3 X 10-4, and atrazine’s
REP was 7.9 X 10-6.
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Table 1. Trans-Nonachlor, PCB-126, and PCB-153 Means Levels for NHANES 99-00, 01-02,
and 03-04 (CDC, 2005)(64): The mean lipid adjusted and wet weight serum concentrations for
trans-nonaclor, PCB-126, and PCB-153 in NHANES 1999-2004 participants are given in Table 1.
The mean trans-nonachlor lipid adjusted concentrations ranged from 18.3 – 14.7 ng/g (41 – 31 nM)
and decreased over time. The trans-nonachlor wet weight means ranged from 0.11 – 0.09 ng/g
(248 – 203 pM) and were higher than the IC50 for EGFR inhibition (0.03 fM). PCB-126 mean lipid
adjusted concentrations varied from 0.023 – 0.016 ng/g (71 – 50 pM) and decreased over time.
The PCB-126 wet weight mean varied between 0.00015 – 0.0001 ng/g (460 – 307 fM) and was
higher than the IC50 for EGFR inhibition (0.09 fM). The PCB-153 mean lipid adjusted concentration
was 27.2 – 19.8 ng/g (75 - 55 nM) and decreased over time. The PCB-153 wet weight mean ranged
from 0.17 – 0.12 ng/g (471 – 332 pM) and was greater than the IC50 for EGFR inhibition (363 fM).
These data demonstrate that the levels measured in humans may be relevant for future
investigation of adverse effects due to EGFR inhibition by these chemicals.
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Trans-nonachlor, chlordane, PCB-126, PCB-153, and atrazine prevent EGF-mediated EGFR
and ERK phosphorylation in A-431 cells at the IC50 concentration
To determine if exposure to the respective IC50 values for these compounds would diminish EGFR
phosphorylation and downstream signaling EGFR Y1173 and ERK phosphorylation were
measured at the IC50 concentrations previously determined by the EGF endocytosis assay. A-431
cells were pre-treated with compounds at the respective IC50 values followed by a 30-minute
treatment with EGF at 20 ng/mL. Protein was then extracted, and western blot analysis was
conducted to measure phosphorylation of EGFR and effector kinase ERK1/2 (Fig 15a-b).
Chlordane (p<0.02, p<0.02), trans-nonachlor (p<0.019, p<0.05), PCB-126 (p<0.02, p<0.05), PCB153 (p<0.03, p<0.03), and atrazine (p<0.03, p<0.05) exposure significantly diminished EGFR and
ERK phosphorylation respectively, at their respective IC50 values. These results demonstrate that
these compounds can prevent EGF mediated EGFR phosphorylation and downstream signaling.
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Figure 15. Chlordane, trans-nonachlor, PCB-126, PCB-153, and atrazine prevent EGFmediated phosphorylation at the IC50 value from the EGF endocytosis assay: A-B. To test
whether EGFR Y1173 and ERK phosphorylation was diminished concordantly at the measured
IC50 for loss of EGF endocytosis, A-431 cells were exposed to the IC50 concentration for the
respective compounds and EGFR Y1173 and ERK phosphorylation were measured via western
blot analysis after EGF treatment. An n = 4 was used and values are represented as mean ± SEM.
Quantitated band densities were statistically compared to the EGF positive control values by an
unpaired, two-tailed t-test. A * denotes P<0.05 which is considered statistically significant.
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Trans-nonachlor, chlordane, PCB-126, and PCB-153 can displace bound 555-EGF from the
EGFR but not atrazine
Next, to determine if these compounds act as competitive inhibitors that can displace bound
fluorescent EGF from the ligand-binding domain of the EGFR a competition assay with fluorescent
EGF administration before the chemical was conducted. A-431 cells on ice were treated with 20
ng/100 µL of Alexa-Fluor 555-EGF for 2.5 minutes and then exposed to 1 pM of either PCB-126,
PCB-153, trans-nonachlor, chlordane (0.041 pg/100 µL), or 100 pM of atrazine for 2.5 minutes.
Cells were then incubated at 37° C for 25 minutes to continue the endocytosis reaction (Fig 16).
Chlordane (p<0.0002), trans-nonachlor (p<0.0001), PCB-126 (p<0.0001), and PCB-153
(p<0.0008) were all able to significantly displace fluorescent EGF from interaction with EGFR
similarly to non-labeled EGF. Atrazine (p<0.94) was unable to displace fluorescent EGF from its
interaction with the EGFR and had similar signal intensity as seen with the DMSO positive control.
These findings would suggest that chlordane, trans-nonachlor, PCB-126 and PCB-153 are
competitive antagonists, while atrazine appears to be an EGFR antagonist that cannot prevent
EGF endocytosis once already bound.
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Figure 16. Trans-nonachlor, chlordane PCB-126, and PCB-153, but not atrazine, displace
EGF from the EGF ligand binding domain of the EGFR: A-431 cells were treated with 20 ng/100
µL of fluorescent EGF for 2.5 minutes on ice to allow EGFR binding but to prevent endocytosis.
Cells were then exposed to 1 pM of trans-nonachlor, PCB-153, PCB-126, 0.041 pg/100 µL of
chlordane, and 100 pM of atrazine for 2.5 minutes while on ice. The cells were then put in the
incubator at 37° C for 25 minutes. Then cells were fixed and stained and EGF spots per nuclei were
measured as previously described. An n = 16 was used and the data are represented as mean ±
SEM. Experimental groups were statistically compared to positive control cells (0.1% DMSO) by
one-way ANOVA. A * denotes P< 0.05, ** P<0.01, *** P<0.001, and **** P<0.0001 was considered
statistically significant.
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Trans-nonachlor, PCB-153, and PCB-126 are predicted to bind within the extracellular
domain of EGFR, while atrazine is predicted to bind to the ATP-binding pocket of the
tyrosine kinase domain
At this stage, chlordane, trans-nonachlor, PCB-126, PCB-153, and atrazine were demonstrated to
ablate EGF endocytosis, and EGF signaling with two measures in two human cell lines. Next, to
elucidate where these compounds are predicted to bind EGFR, protein-ligand docking simulations
were performed.

Since there are currently no available protein structures for pre-formed

unliganded dimers or tetramers of EGFR, an inactive EGFR monomer structure (1NQL) and an
EGFR tyrosine kinase structure (4HJO) were used for the docking simulations (116, 119). This
allowed for the identification of where the various chemicals are predicted to bind in the single
monomer state of the EGFR. As seen in Fig 17a, trans-nonachlor was predicted to bind within a
hydrophobic pocket between domains II and IV (red) and domain IV (blue) of EGFR with an affinity
of -5.8 kcal/mol for both sites. PCB-126 was predicted to bind within a hydrophobic pocket of
domain III (red) and domain II (blue) with an affinity of -6.1 and -5.9 kcal/mol respectively (Fig 17b).
PCB-153 was predicted to bind within a hydrophobic pocket between domain II and IV (red) of and
domain IV (blue) of EGFR with an affinity of -5.9 and -6.1 kcal/mol respectively (Fig 17c). In striking
contrast, atrazine was predicted to interact within the tyrosine kinase domain in the ATP binding
pocket with an affinity of -5.6 kcal/mol (red) and at another site within the TK domain at -5.5 kcal/mol
(blue) (Fig 17d).
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Figure 17. Predicted binding sites for trans-nonachlor, PCB-126, PCB-153, and atrazine with
the EGFR: Small molecule docking simulations with the compounds (A. trans-nonachlor, B. PCB126, C. PCB-153) (structures obtained from PubChem, PubChem IDs found within methods) and
the extracellular domain of EGFR (INQL). D. Atrazine was modeled with the inactive EGFR RTK
domain (4HJO). The EGFR structure and compounds were prepared in Chimera and docking
simulations were conducted using AutoDock Vina software. The models show the two most
energetically favorable sites and the hydrophobicity of the amino acids within those predicted sites.
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DISCUSSION
Initially the well-characterized CAR-activating chlorinated compounds were determined to
not directly activate mCAR relative to the direct mCAR ligand, TCPOBOP in cell culture. This led
to the evaluation of their potential roles as EGFR inhibitors that possibly indirectly activate CAR
through phosphorylation as has been previously demonstrated for phenobarbital and PCBs (19,
96). Interestingly trans-nonachlor, chlordane, and atrazine all had a significant effect in preventing
EGF-mediated EGFR phosphorylation in HepG2 cells. At this stage, these compounds were
investigated further to understand how they act on the EGFR.
The EGFR has 4 sequential and highly regulated steps for activation including I) EGF
binding to an inactive EGFR monomer generating an active monomer, II) homo or
heterodimerization of ligand bound monomers, III) autophosphorylation by the tyrosine kinase
domain, and IV) endocytosis (124, 125). Using these regulatory steps of EGFR activation, the
experimental design was developed to investigate at what step these chemicals are eliciting their
inhibitory effects. The fluorescent EGF assay was used to measure EGF-EGFR endocytosis in the
presence of the chemicals tested. Subsequently, the effect of these chemicals on EGFR
phosphorylation was determined by western blot analysis. These assays paired with the structural
modeling was used to determine how these chemicals ablate EGFR signaling.
Previously published studies in cell-based competition assays have determined that there
are low and high affinity sites for EGF binding (33, 121, 122). Currently it is hypothesized that
roughly 10% of EGF receptors are in the high affinity conformation which are either pre-formed
non-liganded dimers or potentially tetramers (123, 126). The other 90% of EGF receptors are
hypothesized to be in the single monomer conformation or the low affinity state. This is an important
concept as the concentration curves from the fluorescent EGF assay demonstrate two-site binding
which may be representative of a low affinity and high affinity conformation of the EGFR. The data
presented suggest that the amount of high affinity receptors may have been previously
underestimated at 10%. Collectively the data suggest that the amount of high affinity receptors in
the A-431 cells may be as high as 30% of the total receptors. The low affinity site seems more
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sensitive to EGF than in previous studies. This may be due to differences in the EGF label
(fluorescent vs. radiolabeled) and the reaction temperature (37 °C vs. 4 °C) (127).
While trans-nonachlor, PCB 126, PCB 153, and atrazine were potent at preventing EGF
endocytosis, confirmation that the phosphorylation cascade was disrupted was necessary to
validate these compounds as EGFR signaling disrupting chemicals. At the respective
concentrations of the IC50 values for the chemicals, both EGFR phosphorylation and ERK1/2
phosphorylation were reduced. This demonstrated that multiple steps of the EGFR activation
mechanism were prevented by exposure to these compounds.
The EGF displacement assay demonstrated that trans-nonachlor, PCB-126, PCB-153, and
chlordane can apparently displace bound fluorescent EGF from interacting with the EGFR. This
suggests that these compounds are competitive antagonists that interact with the extracellular
domain of the EGFR. Further ligand-receptor docking studies found that trans-nonachlor, PCB126, and PCB-153 interact with hydrophobic residues within the extracellular domain of EGFR.
Interestingly, atrazine could not compete off bound EGF from EGFR, and thus it may bind within
the ATP pocket of the tyrosine kinase domain of EGFR and not at the hydrophobic pocket between
domains II and IV of EGFR. Since these compounds are structurally diverse and EGFR has multiple
regulatory activation steps, it seems logical that environmental chemicals could differ in their
method of EGFR inhibition. Atrazine appeared to act as a tyrosine kinase inhibitor as EGF was
able to stay bound in the presence of atrazine.
While some of the compounds tested were not potent EGFR inhibitors including lindane, DDE,
DDT, alachlor, and dieldrin this does not rule out the possibility that these compounds could disrupt
the signaling of other related receptor tyrosine kinases (RTKs). This has already been
demonstrated for phenobarbital and the insulin receptor (128). Since many RTKs have highly
homologous tyrosine kinase domains, the downstream effects of receptor inaction could overlap
(129, 130).
While the EGF endocytosis assay was previously published as a tool for high throughput
EGFR inhibitor screening for EGFR-directed chemotherapy discovery, it may also serve as a
chemical adverse effect screen (114). Fifty-two percent of exogenously administered EGF traffics
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to the liver in animals, and recently EGFR signaling has been shown to regulate 25% of the liver
phosphoproteome during the inactive phase in mice (28, 98). EGFR signaling is essential not only
in liver homeostasis, but in the pancreas as well. EGFR signaling promotes insulin secretion in bcells and insulin levels have been observed to be decreased in patients administered EGFR
inhibitors (53, 131-133). EGFR inhibition or loss of function is linked to the development of skin
rashes and skin inflammation (105, 106, 109, 110, 134). In fact, some of the compounds tested in
this study cause a skin rash and related toxic responses upon exposure which is commonly referred
to as chloracne (7, 81-86). This chloracne may be mechanistically distinct from the chloracne
observed in people exposed to high levels of TCDD. EGFR signaling is also crucial in development
and is highly expressed in the placenta. Diminished placental EGFR phosphorylation was observed
in Yu-cheng women exposed to PCBs which correlated to lower birth weights (33, 121). Since
EGFR signaling is physiologically relevant in liver, pancreas, skin, and in utero development this
receptor-internalization assay should be considered for screening new chemical compounds for
adverse health effects. Many EPA high-throughput screens focus on chemical-induced modulation
of nuclear receptor activity, but new assays for RTKs should be considered as well. Since RTK
activity regulates almost every facet within the cell including nuclear receptor activity, they should
also be considered in adverse outcome chemical testing. The data demonstrate that although the
structures of these compounds are diverse, they act through EGFR inhibition. This may allow for
an additive risk assessment between these different classes of compounds for a variety of maladies
including liver disease, pancreatic dysfunction, skin irritation, and developmental defects. Future in
vivo studies will evaluate whether the compounds tested promote endocrine and metabolic
disruption in a EGFR-dependent manner.
The mean serum levels of trans-nonachlor, PCB-126, and PCB-153 in NHANES
demonstrate that many people in the general population may be at risk for EGFR inhibition by
environmental chemicals. The IC50 Values shown for the various EGFR inhibitors appear low and
similar too or less than the human serum concentrations of these compounds.

As these

compounds are hydrophobic, with very high hexane:water partition coefficients, these compounds
will accumulate on the cell surfaces of the monolayer rather than being evenly distributed in the
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culture media. Likewise, the in vivo distribution of these compounds is very dependent on the
pharmacokinetics of body distribution, being much higher in adipose, and potentially fatty liver.
Thus, the observed IC50 may be considerably lower than the serum concentration that is likely to
manifest itself as EGFR inhibition in vivo. Future work is needed to establish what serum
concentrations of these chemicals elicits EGFR inhibition in varied tissues in vivo leading to adverse
effects.
Current risk assessment measures for adverse effects due to environmental exposures are
limited. For dioxins acting through the aryl hydrocarbon receptor, toxic equivalency factors (TEFs)
and toxic equivalencies (TEQs) have been determined, in part, through REP data (135). TEQ
allows for analysis of the health effects of mixtures of dioxins with varying potencies. REPs for
some environmental chemicals inhibiting EGFR were generated in this dissertation. Since the
fluorescent EGF assay is a high throughput it may serve as a preliminary toxicity evaluation tool for
other chemicals, generating additional REPs. If EGFR inhibition by environmental chemicals is
additive, TEFs and TEQs for EGFR inhibiting chemicals could be generated in the future to aid in
the evaluation of complex mixtures of these chemicals. I propose that this could be done in a
fashion similar to what was developed for dioxins.
This study demonstrates that EGFR inhibition is a conserved mechanism for diverse
EDCs/MDCs that were previously characterized as CAR activators. The high throughput methods
used in this investigation may provide a model system for adverse outcome evaluation of new
chemicals being manufactured. PCB-126, PCB-153, and trans-nonachlor are likely competitive
antagonists of EGF binding to EGFR. In contrast, atrazine appears to act as a tyrosine kinase
inhibitor that was predicted to bind to the ATP pocket of the EGFR TK domain. The predicted
binding sites are indicative of hydrophobic interactions with nonpolar amino acids of the EGFR.
Furthermore, this study establishes human specific REPs for EGFR signaling disrupting chemicals
(SDCs) and documents two mechanisms for this inhibition. Future studies should determine if
atrazine, trans-nonachlor, and chlordane diminish EGFR signaling in vivo similar to PCBs (96).
Epidemiological studies should test whether exposure to these SDCs have additive risk for
developmental, dermatological, and metabolic diseases.
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CHAPTER 4
PROTEOMIC ANALYSIS REVEALS MECHANISMS BY WHICH POLYCHLORINATED
BIPHENYLS SENSITIZE THE LIVER TO DIETARY STEATOHEPATITIS

INTRODUCTION

Proteomics is a well-established discovery tool in both hepatology and environmental
health research. In this study I aimed to characterize the proteomic alteration do to PCBs and a
HFD. Based On the proteomic data I conducted pathway analysis and transcription factor analysis
to elucidate mechanism for PCB-mediated steatohepatitis. Previously some PCBs have been
shown to activate human and murine aryl hydrocarbon receptor (AhR) and some nuclear receptors
[e.g., the pregnane x receptor (PXR) and the constitutive androstane receptor (CAR)]; while
inhibiting epidermal growth factor receptor (EGFR) signaling (3, 36, 96, 139, 140). Knocking out
PXR or CAR modulated but did not prevent the steatohepatitis associated with Aroclor 1260 and
high fat diet co-exposures, implicating additional mechanisms (18). Nuclear receptor modulation
by PCBs in the context of NAFLD is clinically relevant as activation of many hepatic nuclear
receptors such as farnesoid X receptor (FXR), liver X receptor alpha (LXRa), and peroxisome
proliferator-activated receptors (PPARs) is considered therapeutic and many agonists for these
receptors are in clinical trials currently (141, 142). I hypothesize that liver proteomics would discover
new mechanisms for PCBs in liver disease progression using our established mouse model (3).
Selected mechanisms were validated, and the potential influence of epidermal growth factor
signaling was investigated in some cases.
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MATERIALS AND METHODS

Animal Exposures
The mouse liver samples used in this study were obtained from archived (-80°C) tissues from a
prior study (3). The workflow of this study is illustrated in figure 18A. Further description of these
mice and samples can be found in chapter 2.

Peptide Extraction, LC/MS/MS Analysis, MetaCore Analysis, and Data Sharing
Three samples per group were randomly selected for proteomic analysis. Mouse livers were
homogenized in 1% SDS RIPA buffer. Proteins were reduced with DTT followed by denaturation
with 8M Urea, alkylation with iodacetamide, these reagents were purchased from Sigma-Aldrich
(St. Louis, MO). Peptides were digested with Trypsin purchased from Promega (Madison, WI)
followed by enrichment and clean up with C18 filters purchased from The Nest Group
(Southborough, MA). Protein lysates (100 µg per sample) were trypsinized using filter aided sample
preparation (144). Peptide concentrations were measured by a bicinchoninic acid assay, and equal
amounts of peptides were injected into the high-performance liquid chromatography machine in a
0.1% formic acid and 80% acetonitrile gradient. A Finnigan LTQ mass spectrometer
(ThermoFisher) was used to collect mass spectral data from the LC eluate. The generated msf file
from Proteome Discoverer were loaded into Scaffold Q+S v4.4.5. Scaffold was used to calculate
the false discovery rate (FDR) using the Peptide and Protein Prophet algorithms.

MetaCore Analysis
Cellular Localization Analysis, Pathways and Processes Analysis, and Transcription Factor
Analysis (TFA) were performed using Metacore Software (Clarivate Analytics, Philadelphia, PA).
Hepatic proteins that had significantly differential abundance (p-value < 0.05, by two-way ANOVA
examining the diet and exposure factors) were analyzed by MetaCore software (Clarivate Analytics,
Philadelphia, PA). Results that met the FDR threshold (< 0.05) were accepted. Transcription factors
are listed by highest activity (largest z-score/target gene differential) to the lowest activity.
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The data was analyzed with Proteome Discoverer v1.4.1.14. The database used in the Mascot
v2.5.1 and SequestHT algorithms was the 3/7/2016 version of the UniprotKB Mus musculus
reference proteome canonical and isoform sequences with the nonmurine sequences from the
1/1/2012 version of thegpm.org cRAP database appended to it. For the MetaCore TFA, when
making direct comparisons between proteins of the HFD mice and the HFD plus Aroclor coexposed mice, a criterion of at least a 3-fold increase or 2-fold decrease was used to select the
proteins analyzed (Fig S3). Data files for acquired LCMS data (.RAW), search engine files (.mgf),
peak list files (.mzML) files, and search results aggregated into a Scaffold3 (.sf3,
ProteomeSoftware.com) will be deposited with MassIVE (http://massive.ucsd.edu/) data repository
with the Center for Computational Mass Spectrometry at the University of California, San Diego
and shared with the ProteomeXchange (www.proteomexchange.org)

Cell Culture
Hepatocyte nuclear factor 4 alpha (HNF4a) phosphorylation assay
AML-12 (CRL-2254) cells obtained from ATCC (Manassas, VA) were exposed to DMEM/F-12
media containing either EGF (1.2 nM) (EMD Millipore, Burlingtion, MA), Aroclor 1260 (10 µg/mL)
and EGF (1.2 nM),

or 0.5% DMSO for 30 minutes then protein was extracted to measure

phosphorylated Hnf4a, total Hnf4a, phosphorylated Egfr and total Egfr.
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) protein stability assay
A-431 (CRL-1555) cells obtained from ATCC (Manassas, VA) were exposed to media containing
either EGF (1.2 nM), Aroclor 1260 (10 µg/mL) and EGF (1.2 nM), or 0.5% DMSO for 2 hours then
protein was extracted to measure total Nrf2 and b-actin.
Hepatic Stellate Cell (HSC) activation assay
LX-2 cells were obtained from Sigma-Aldrich (St. Louis, MO) while HepG2 cells (HB-8065) were
obtained from ATCC (Manassas, VA). Initially LX-2 and HepG2 cells were cultured in DMEM media
containing either 10 µg/mL of Aroclor 1260, or 0.5% DMSO. RNA was extracted at 24 hours, and
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48 hours. Subsequently, some LX-2 cells were treated with conditioned media from the HepG2
cells and RNA was again prepared.
HepG2 cells are a male human hepatoblastoma cell line. AML-12 cells are mouse hepatocytes
derived from a male transgenic mouse that expresses human TGFα. A-431 is a human epidermoid
carcinoma cell line derived from a female patient. LX-2 cells are a human stellate cell derived cell
line.

Cells were seeded at 1X104 per well in 12-well plates and grown to confluence for 24 hours. HepG2,
A-431 and LX-2 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (VWR, Radnor,
PA) supplemented with fetal bovine serum and 1% antimycotic/antibiotic solution (Mediatech,
Manassas, VA).

AML-12 cells were grown in 1:1 DMEM/F12 media (VWR Radnor, PA)

supplemented with ITS Universal Culture Supplement Premix (VWR Radnor, PA), dexamethasone
(40 ng/ml), 1% antimycotic/antibiotic solution (Mediatech, Manassas, VA) and 10% fetal bovine
serum (VWR Radnor, PA). The cells were incubated in a 5% carbon dioxide atmosphere and 95%
humidity at 37° and sub-cultured every 2 days.

Western Blot Analysis

Liver tissue and cells were lysed in RIPA Buffer (100 mg tissue/0.5 mL RIPA supplemented with
protease, and phosphatase inhibitors (10 µL/mL, Sigma-Aldrich, St. Louis, MO). The following
antibodies were used and purchased from Abcam (Cambridge, MA): Hnf4a, Nrf2, Y1173 EGFR;
Thermo-scientific (Waltham, MA): S313 Hnf4a; Cell Signaling Technology (Danvers, MA): b-actin;
and Santa Cruz (Dallas, TX) EGFR. Full description of western blot analysis methods can be found
in chapter 2.

Real-time PCR Analysis
Mouse livers or cells were homogenized, and total RNA was extracted using the RNA-STAT 60
protocol (Tel-Test, Austin, Texas). RNA integrity and quantity were determined with the Nanodrop
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(ND-1000, Thermo Scientific, Wilmington Delaware) using the ND-1000 V3.8.1 software package.
cDNA was synthesized from total RNA using the QuantiTect Reverse Transcription Kit (Qiagen,
Valenci, California). PCR was performed on the BioRad CFX384 Real-Time System using the
BioRad iTaq Universal Probes Supermix. Taqman Gene Expression Assays (Thermo-Fisher).
Gene expression levels were calculated according to the 2-DDCt method, and Gapdh was used as
the endogenous control.
The following primers were used obtained from Applied Biosystems (): Actin alpha 2, smooth
muscle,

aorta

(Acta2);

(Hs00426835_g1)

Alpha

tocopherol

transfer

protein

(Ttpa),

(Mm00803828_m1); Aryl hydrocarbon receptor (Ahr); (Mm00478932_m1), Cytochrome P450,
family 2, subfamily c, polypeptide 29, (Cyp2c29), (Mm00725580_s1), Eukaryotic translation
initiation factor 4b (Eif4b); (Mm00778003_s1), Glyceraldheyde-3-phosphate dehydrogenase
(Gapdh); (Mm99999915_g1) (Hs02786624_g1); Glutamate-cysteine ligase catalytic subunit (Gclc);
(Mm00802655_m1), Glutathione S-Transferase Mu 1 (Gstm1); (Mm00833915_g1), Malic enzyme
1 (Me1); (Mm00782380_s1), Myocyte enhancer factor 2c (Mef2c); (Mm01340842_m1), NAD(P)H
quinone oxidoreductase (Nqo1); (Mm01253561_m1), Platelet derived growth factor alpha (Pdgfa);
(Hs00234994_m1), Perilipin-2 (Plin2); (Hs00605340_m1), Pyruvate kinase liver and RBC (Pklr);
(Mm00443090_m1), and Transforming growth factor-beta (Tgf-b); (Hs00998133_m1). Gapdh was
used as a control.

Total Glutathione Assay
Total glutathione concentration was determined by the method of Griffith (145, 146). Liver tissue
was homogenized in PBS and centrifuged allowing determination of total thiol (predominately
glutathione) through a colorimetric recycling assay at 412 nm. Total glutathione was normalized to
liver protein.

Statistical Analysis
Western blot densitometry values, RNA expression values, and glutathione measurements were
statistically analyzed using Graphpad Prism Version 7 for Macintosh (San Diego, CA). The data

66

are expressed as box and whisker plots. Western blot analysis data in figure 21C were compared
using one-way ANOVA. qPCR data in figure 23A-C were statistically compared using an unpaired
t-test. All other in vitro and in vivo datasets were compared using two-way ANOVA. P<0.05 was
considered statistically significant. Quantified peptides from MS analysis were statistically
compared by two-way ANOVA with a looping two-way ANOVA script in R software package.

RESULTS
Liver proteomic analysis identifies protein alterations due to HFD, Aroclor 1260, and their
interaction in a steatohepatitis mouse model
Mice fed a HFD developed dietary steatosis, but mice fed a HFD and exposed to Aroclor 1260
developed steatohepatitis (57). Control diet fed mice exposed to Aroclor 1260 did not develop
steatosis or steatohepatitis (Fig 18A). Significant alterations with protein expression occurred with
Aroclor 1260 exposure (154 increased, 93 decreased), HFD (239 increased, 137 decreased), and
their interaction (60 increased, 179 decreased) (Fig 18B). These raw mass spectrometry data have
been deposited in the MassIVE data repository. Cellular localization of proteins affected is shown
in Figure 18C. The proteins significantly altered by a HFD are localized primarily in the mitochondria
(p=3e-25) and ER (p=3.5e-19). Proteins significantly altered by Aroclor 1260 exposure are localized
primarily within cytoskeleton, (p=8.4e-10). Proteins localized to cytoskeletal regions (p=8.6e-7), were
also significantly affected by the interaction of a HFD and Aroclor exposure.
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Figure 18. Liver proteomic analysis identifies proteomic alterations due to HFD, Aroclor
1260, and their interaction in a steatohepatitis mouse model: A. Proteomic analysis workflow
of mouse liver sample to characterize the hepatic events in the progression of dietary steatosis to
steatohepatitis. B. Significant (p=0.05) differential abundances of hepatic proteins due to a HFD,
Aroclor 1260 exposure, and their interaction. C. Cellular localization of the significant proteins for
each variable. Three biological replicates per group was used for the proteomic analysis (12 in
total). Peptide abundances were compared by two-way ANOVA and only peptides that were
significant (p<0.05) were investigated further.
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Figure 19. Linear relationship of peptide expression between biological replicates in
LC/MS/MS: The relative peptide value from each of the biological replicates of each group has a
linear relationship with the mean of each quantitative peptide value as is shown in Fig 19A-C. Mean
vs. replicate 1 (R2 = 0.63), Mean vs. replicate 2 (R2 = 0.62), Mean vs. replicate 3 (R2 = 0.61)
demonstrate that the quantitative values for each protein are similar between biological replicates
for each of the respective groups.
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Pathway and processes analysis of proteins altered by either a HFD, Aroclor exposure, or
their interaction

A number of pathways and processes were significantly affected by HFD (n=78), Aroclor 1260
(n=30), or the interaction between the two (n=55). These full results are provided in Tables 2,3,4,
and a subset of these are summarized in Fig. 19. Pathways altered by HFD included enhanced
endoplasmic reticulum (ER) stress (p=3.02e-13) and diminished oxidative phosphorylation (p=8e-5).
These findings are consistent with previously published studies (147, 148). Pathways and
processes altered by Aroclor exposure included cytoskeletal processes and muscle contraction
(p=5.8e-13), possibly consistent with hepatic stellate cell activation (149); and reduced FXR
regulation of glucose and lipid metabolism (p=0.002). Aroclor 1260 and HFD interacted to enrich
similar cytoskeletal pathways (p=0.0001); while diminishing glutathione metabolism (p=4e-5); and
altering intermediary metabolism.
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Figure 20. Pathway analysis of proteins altered by either a HFD, Aroclor exposure or their
interaction: A. –Log(p-value) plots and pathway analysis of proteins significantly altered by HFD,
B Aroclor exposure, or their C interaction. Complete list of pathways, processes and statistics are
listed in tables 2,3,4 in the supplementary data. All pathways and processes identified through
MetaCore analysis had to meet a FDR threshold <0.05.
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Table 2. Full list of pathways and processes significantly increased or decreased by a HFD:
All of the significant pathways and processes that are representative of the significant peptides
(p<0.05) due to a HFD.
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Table 3. Full list of pathways and processes significantly increased or decreased by Aroclor
1260 exposure: All of the significant pathways and processes that are representative of the
significant peptides (p<0.05) due to a Aroclor 1260 exposure.
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Table 4. Full list of pathways and processes significantly increased or decreased by
interaction of a HFD and Aroclor exposure: All of the significant pathways and processes that
are representative of the significant peptides (p<0.05) due to an interaction.
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Transcription factor analysis (TFA) results

TFA predicted significant alterations in transcription factor activity with HFD (n=51), Aroclor 1260
(n=42), or their interaction (n=19) (Table 5A-C). HFD increased activity of transcription factors
associated with cellular stress [e.g., transcription factor AP-1 (cJun) (p=5.5e-5), and nuclear factor
NF-kappa-B p65 subunit (NFkB) (p=0.004)]; and ER stress [e.g., activating transcription factor-6
(ATF-6) (p=1.3e-7), activating transcription factor-4(ATF-4) (p=0.0006), and X-box binding protein1 (XBP1) (p=0.0008)]. Aroclor exposure increased transcriptional activity of the myofibroblast
specific transcription factors, myogenic differentiation factor 1 (MYOD) (p=0.0007) and BarH-like
homeobox gene 2 (BARX2) (p=3.3e-5). The interaction between HFD and Aroclor decreased the
transcriptional activities of NRF2 (the central regulator of the antioxidant response, p=0.0002) and
five nuclear receptors [e.g., HNF4a (p=0.0004), hepatocyte nuclear factor gamma (HNF4γ)
(p=0.002), estrogen receptor 1 (ESR1) (p=0.0002), thyroid receptor beta (TRβ) (p=0.0004), and
LXRα (p=0.0004)]. The observed reduction in HNF4α could be pathologically meaningful because
HNF4α is a key regulator of hepatocyte differentiation and function. The preceding results were
determined by two-way ANOVA. TFA was also performed through comparison of the HFD plus
Aroclor 1260 (HFD+) vs. HFD treated groups of mice by fold-change thresholds (Table 6). Although
some differences exist in the TFA results generated by the different methods, NRF2 and HNF4α
remained negatively regulated in both. Myocyte enhancer factor 2c (MEF2C), a positive regulator
of HSC activation was increased (p=1.6e-06) in HFD+ vs. HFD. By and large, the TFA results
support the pathway and process results. Based on consistency, intermediary metabolism
(HNF4α), glutathione metabolism (NRF2), and cytoskeletal remodeling/fibrosis (MEF2C) were
validated.
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Table 5. Transcription factor analysis results: TFA of proteins significantly diminished or
enriched by experimental variables. Table 5A. HFD, Table 5B. Aroclor exposure, or Table 5C.
interaction. All the transcription factors identified by MetaCore analysis had to meet a FDR
threshold <0.05.
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Table 6. Transcription factor analysis of HFD vs HFD+ (steatosis vs. steatohepatitis) peptide
data: Transcription factors determined to have increased or decreased activity based on the
peptide fold-changes in steatosis as compared to steatohepatitis samples are listed in Table 6.
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Aroclor 1260 reduced HNF4a protein expression and activity, and HNF4α is a downstream
phosphorylation target of the EGFR

Aroclor 1260 exposure significantly reduced HNF4a protein levels (p=0.02) in mice fed either
control diet (56% decrease) or HFD (47% decrease); and HFD significantly reduced HNF4α mRNA
levels (p=0.006, Fig. 20Ai-ii). Proteomics demonstrated that several HNF4a target genes were
reduced by Aroclor 1260 at the protein level, so mRNA expression for some of these was
determined. Albumin mRNA was reduced by Aroclor 1260 exposure (p=0.0001), and was markedly
suppressed (78%, HFD+ vs. HFD) by a pollutant-diet interaction (p=0.0003, Fig. 20Bi). Likewise,
cytochrome P450 family 2 subfamily c (Cyp2c29) mRNA was decreased 7.6% in HFD+ vs. HFD by
a pollutant-diet interaction (p=0.03, Fig. 20Bii). Ttpa (tocopherol transfer protein) was diminished
12.2% in HFD+ vs. HFD due to interaction (p=0.01, Fig. 20Biii).

Since PCBs disrupt EGFR signaling, interactions between EGF and PCBs on HNF4α were
evaluated in vitro (Fig. 20C). Compared to vehicle control, EGF treatment significantly increased
the relative phosphorylation of both EGFR (p=0.02) and HNF4α (p=0.02) in AML-12 cells (Fig.
20Ci-ii). These changes were attenuated by Aroclor 1260 exposure as seen by a 46% decreased
in EGF vs. EGF+A1260 for phosphorylated EGFR; and a 63% decrease for phosphorylated HNF4α
(Fig. 20Ci-ii). Expression of the HNF4a target gene, pyruvate kinase, liver and RBC (Pklr) was
increased by EGF (p=0.0005) at the mRNA level, and this was attenuated 26% by Aroclor 1260
(p=0.002, Fig. 20D). In total, these data demonstrate that HNF4α protein, but not mRNA
expression, is downregulated by Aroclor 1260 exposure. HNF4α function was reduced by Aroclor
1260 and/or the interaction between Aroclor 1260 and HFD. The latter interaction may potentially
contribute to the observed transition from steatosis to steatohepatitis. Reduction in EGF-dependent
HNF4α phosphorylation by PCBs partially explains the diminished HNF4α activity. These data
validate the observed alterations in some of the intermediary metabolism pathways/processes and
TFA.
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Figure 21. Aroclor 1260 reduced HNF4a protein expression and activity, and HNF4α is a
downstream phosphorylation target of the EGFR: A. (i) Immunoblot analysis, and (ii) RT qPCR
analysis of hepatic HNF4a protein and mRNA from mice fed a control diet (CD), control diet and
exposed to Aroclor 1260 (20 mg/kg) (CD+), fed a HFD (HFD), and fed a HFD and exposed to
Aroclor 1260 (20 mg/kg) (HFD+). B. RT qPCR Analysis of HNF4a target genes (i) Albumin, (ii)
Cyp2c29, and (iii) Ttpa from murine liver. C. Western blot analysis of (i) Y1173 EGFR and (ii)
HNF4a S313 phosphorylation in AML-12 cell lysates exposed to DMSO (0.5%), EGF (1.2 nM), and
EGF+A1260 (1.2 nM EGF, 10 µg/mL). D. RT qPCR analysis of HNF4a target gene Pklr in AML12s after 6-hour incubation with either DMSO (0.5%), EGF (1.2 nM), EGF+A1260 (1.2nM EGF, 10
µg/mL), or A1260 (10 µg/mL). All data are represented as box and whisker plots. An n=5 was used
for the HNF4a protein levels analysis in vivo, an n=10 for Hnf4a mRNA and HNF4a target gene
mRNA in vivo, an n=4 for HNF4a S313 phosphorylation, and an n=4 for Pklr mRNA. A P<0.05 is
denoted with *. In the in vivo datasets an a denotes significance due to Aroclor, b HFD, and c
interaction. Two-way ANOVA was used to statistically compare the in vivo data. One-way ANOVA
was used for the statistical analysis for Fig 20Ci-ii. A two-way ANOVA was used for the statistical
analysis in Fig 20D; an a denotes significance due to EGF, b due to Aroclor.
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Aroclor 1260 reduced NRF2 protein/mRNA expression and glutathione levels, and NRF2 is
an EGF-sensitive target

Hepatic NRF2 protein and mRNA, and total glutathione were diminished by Aroclor exposure in
vivo (p=0.04, p=0.02, and p=0.03 respectively, Fig. 21Ai-iii). In control diet fed mice, Aroclor 1260
reduced NRF2 protein by 73%, NRF2 mRNA by 28%, and glutathione by 67%. In HFD-fed mice,
Aroclor 1260 reduced NRF2 mRNA by 16%, glutathione by 51%, and NRF2 target gene mRNA
[NAD(P)H quinone dehydrogenase 1 (Nqo1), glutathione s-transferase mu 1 (Gstm1), and malic
enzyme 1 (Me1)] in liver in vivo (p=0.014, p=0.015, and p=0.004, respectively, Fig. 21Bi-iii). Aroclor
1260 decreased Nqo1 27% in CD-fed mice and 96% in HFD-fed mice; Me1 37% in CD-fed mice
and 60% in HFD-fed mice; and Gstm1 64% in HFD-fed mice. Glutamate-cysteine ligase catalytic
subunit (Gclc) was decreased 41% by HFD/Aroclor 1260 interaction (vs. HFD, p=0.045, Fig. 21Biv).

Next, the potential interactive effects of EGF and PCBs were determined on NRF2 protein
expression in vitro (Figure 22C). EGF-treated A-431 cells had significantly higher NRF2 expression
after two hours, suggesting that NRF2 is stabilized by EGF treatment alone as seen by a 72%
increase.

Aroclor 1260 greatly attenuated this effect (p=0.01) as demonstrated by a 49%

decreased with EGF and A1260. These data by and large confirm the results regarding glutathione
metabolism and NRF2 activity from the pathway/processes analyses and the TFA with some
caveats. The protein and gene expression studies demonstrate that the reduction in glutathione
metabolism and NRF2 expression/activity are predominantly Aroclor 1260 effects, rather than
pollutant-diet interaction effects. While the TFA demonstrated that both Aroclor 1260 and the
pollutant-diet interaction impacted NRF2 activity, the glutathione metabolism pathway/process was
only affected by the interaction. PCBs may inhibit EGF-dependent NRF2 stabilization by disrupting
EGFR signaling.
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Figure 22. Aroclor 1260 reduced NRF2 protein/mRNA expression and glutathione levels, and
NRF2 is an EGF-sensitive target: A. (i) Immunoblot analysis, (ii) RT qPCR of hepatic NRF2
protein and mRNA, respectively, and (iii) total glutathione measurements from mice fed a control
diet (CD), control diet and exposed to Aroclor 1260 (20 mg/kg) (CD+), a HFD (HFD), and HFD and
exposed to Aroclor 1260 (20 mg/kg). B. RT qPCR analysis of hepatic NRF2 target genes (i) Nqo1,
(ii), Gstm1, (iii) Me1, and (iv) Gclc in murine liver. C. (i) Immunoblot analysis of NRF2 protein
expression in A-431 cells exposed to either DMSO (0.5%), EGF (1.2 nM), EGF+A1260 (1.2nM
EGF, 10 µg/mL), or A1260 (10 µg/mL) for 2 hours. A p<0.05 is denoted by a for Aroclor, b for
HFD/EGF or c for interaction in the in vivo datasets. All data are represented as box and whisker
plots. A sample size of 5 was used for the analysis of the NRF2 protein levels in vivo, an n=10 for
NRF2 mRNA and NRF2 target gene mRNA in vivo. An n=4 was used for the NRF2 in vitro assay
and an a denotes significance due to EGF, and c for interaction. Two-way ANOVA was used to
statistically compare all of these datasets for Fig 22.
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Aroclor exposure activates HSCs through hepatocyte-derived TGF-b

Hepatic stellate cells (HSCs) normally store Vitamin A and can transdifferentiate into proliferative
myofibroblasts or “activated” HSCs. Since pathway/process analysis and TFA demonstrate that
cytoskeletal processes were increased by both Aroclor exposure and the pollutant-HFD interaction,
I hypothesized that Aroclor 1260 could activate HSCs. Additionally I aimed to determine if activation
of HSCs is hepatocyte mediated or a direct effect on HSCs. This was tested in vitro. In cultured LX2 cells (immortalized human HSCs), Aroclor 1260 did not directly increase actin, alpha 2, smooth
muscle, aorta (ACTA2) (active HSC marker) or decrease perilipin 2 (PLIN2) (quiescent HSC
marker) mRNA expression (Fig. 22Ai-ii). In contrast, conditioned media from Aroclor 1260-exposed
HepG2 cells increased ACTA2 gene expression in LX-2 at 48 hours by 93% (P=0.006, Fig. 22Biii). PLIN2 was unaffected. Aroclor 1260 exposure increased expression of the key fibrogenic
cytokine, transforming growth factor-beta (TGF-b), in HepG2 cells by 45% (p=0.03, Fig. 22Cii, but
did not change platelet derived growth factor alpha (PDGFα) expression (Fig 22Ci). Hepatic mRNA
expression of MEF2C was significantly increased by 28% (HFD+ vs. HFD) by Aroclor 1260
exposure in vivo, confirming TFA results. These data confirm the proteomics results and suggest
that PCBs may be pro-fibrotic. PCB-induced stellate cell activation may be indirectly mediated by
hepatocyte-derived TGF-b.
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Figure 23. Aroclor exposure activates HSCs through hepatocyte-derived TGF-b: A. RT qPCR
analysis of (i) ACTA2 and (ii) PLIN2 in LX-2 cells directly exposed to either DMSO (0.5%) or A1260
(10 µg/mL) for 24 or 48 hours. B. RT qPCR analysis of (i) ACTA2 and (ii) PLIN2 in LX-2 cells
exposed to HepG2 media from HepG2 cells exposed to either DMSO (0.5%) or A1260 (10 µg/mL)
for 24 hours. C. Gene expression analysis of (i) PDGFa and (ii) TGF-b in HepG2 cells directly
exposed to either DMSO (0.5%) or A1260 (10 µg/mL) for 24 hours. D. RT qPCR analysis of MEF2C
in murine liver of mice fed a control or HFD with either exposure to Aroclor 1260 (20 mg/kg) or
vehicle control. A p<0.05 is denoted with *, p<0.01 **. A p<0.05 is denoted by a for Aroclor, b for
HFD or c for interaction. A n=4 was used for figure 23A-C, n=10 for figure 23D and the data are
presented as box and whisker plots. A two-tailed t-test was used to statistically compare datasets
Fig 22A-C and a two-way ANOVA for 18D.
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DISCUSSION

While PCBs have long been associated with liver disease in animal models and more
recently, cohort studies, their mode of action remains elusive. This liver proteomics study
demonstrates that the mechanisms of PCBs in fatty liver disease progression are multifactorial and
complex. While PCB research has primarily focused on the positive PCB responses (e.g., activation
of AhR, PXR, CAR, etc.), this study demonstrates that the negative responses to Aroclor 1260
and/or the PCB-HFD interaction generally outnumber the positive ones. Some of the downregulated pathways and processes were related to hepatocyte function (e.g., metabolism of fatty
acids, amino acids, and carbohydrates as well as albumin production) and protection (e.g. the
antioxidant response). Key results from the TFA include the negative regulation of NRF2 and
myriad nuclear receptors previously implicated in NAFLD (e.g., HNF4α, FXR, PPARα/δ/γ, TRα,
ERα, RXRα, etc.). Vitamin E is an established treatment for non-alcoholic steatohepatitis (NASH),
and many nuclear receptor agonists (e.g., FXR, PPARα/δ, TRβ, etc.) are currently being
investigated in NASH clinical trials (150). If antioxidants and nuclear receptor agonists have
therapeutic roles in NASH, it is plausible that their reduction by PCBs may be pathogenic.

While the mechanisms of negative regulation of transcription factors by PCBs is largely
unknown, this dissertation demonstrates that their regulation may be indirect and related reduced
transcription

factor

expression

and

EGF-dependent

phosphorylation.

Perhaps

a

phosphoproteomics study is required in the future. While mice fed control diet and treated with
Aroclor 1260 did not develop NAFLD pathology, the antioxidant and nuclear receptor downregulation should theoretically sensitize these mice to hypercaloric diets (3). This was indeed the
case, as HFD+ mice developed steatohepatitis, while HFD mice developed only steatosis. Human
confirmation of these results is required. However, if confirmed, the results could have meaningful
clinical implications with regards to NASH pathogenesis and treatment. Moreover, it would solve
an important paradox facing endocrine disrupter research. In the US, metabolic diseases like
NAFLD have increased in prevalence while overall environmental pollution has declined. However,
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if low-level pollution sensitizes to the obesity-related diseases mediated by hypercaloric diets, as
suggested by our animal data, then the paradox would be explained.

I propose that progression of dietary steatosis to steatohepatitis is due to a two-hit
paradigm. High fat diet is one hit and PCB exposure being the other (3). Before this study, there
was limited characterization of the mechanisms/processes in the hit of PCB exposure. In contrast,
characterization of the processes in the liver impacted by a HFD are well known, and our results
are consistent with previous studies (147, 148). From the pathway and TFA analysis, ER stress
response and inflammatory pathways and transcription factors are upregulated due to a HFD. This
has been demonstrated in the livers of HFD fed animals previously and ER stress is heavily
implicated in dietary steatosis (147, 148). Mitochondrial dysfunction due HFD downregulation of
oxidative phosphorylation enzymes was observed from the pathway analysis. This is a common
feature in the livers of diet-induced obese mice (151). The first step in the development of dietary
steatosis from a HFD seems to be lipid accumulation promoting ER stress and mitochondrial
dysfunction. PPARa, a key transcriptional regulator of lipid metabolism, was predicted to be
downregulated with Aroclor 1260 exposure but elevated with a HFD which is consistent with
previous studies (3).

It has been demonstrated that PCBs act, in part, through hepatic EGFR inhibition (96, 140).
EGFR signaling is critical for liver function and thus, can affect the expression and activity of many
proteins. EGFR signaling has been shown to regulate nuclear receptors and transcription factors,
but very few studies have characterized its effects on liver identity factors, such as HNF4a. HNF4a
is a critical nuclear receptor for liver function that has been shown to transcriptionally regulate 60%
of liver specific genes; HNF4a-null mice spontaneously develop NAFLD (152). Previously, loss of
HNF4a has been demonstrated in chemical induced liver injury, but has not been shown for PCB
exposure (153) or steatohepatitis (154)

The data demonstrate that HNF4a and its target genes were downregulated in steatohepatitis
similar to other EGF-sensitive transcription factors (96). Albumin, a gene regulated by HNF4a, has
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been shown in human studies to be downregulated with elevated PCBs levels which corroborates
this data (13). HNF4a was then shown to be regulated by EGF signaling by phosphorylation of
HNF4a at S313. The transcription of the HNF4a target gene, Pklr, was also increased with EGF
versus Aroclor 1260 exposure. This EGFR-HNF4a signaling pathway may be very critical for
maintaining liver homeostasis and function (155). Thus, any disruption due to environmental
chemicals may act, in part, to promote steatohepatitis

Pathway analysis and TFA identified both glutathione metabolism and NRF2 as being
downregulated in steatohepatitis. This observation is consistent with our previous metabolomic
studies showing that hepatic glutathione is diminished in a PCB-153 treated HFD fed mouse model
(156). Since NRF2 transcriptionally regulates enzymes involved in glutathione synthesis, it was
important to validate this finding. NRF2 expression and target genes were diminished with Aroclor
exposure in vivo as was total glutathione. NRF2 is the main transcriptional regulator of glutathione
biosynthesis in the liver and loss of NRF2 greatly limits the liver’s endogenous antioxidant capacity.
This loss then creates a more pro-oxidative environment that is implicated in the loss of oxidative
phosphorylation (151). While loss of total hepatic GSH was not exacerbated in HFD+ as compared
to CD+ the GSH:GSSG ratios were not measured. Moreover, the pro-oxidants were not measured.
I postulate that HFD+ would have increased pro-oxidants and a decreased GSH:GSSG ratio. This
means that the transition from steatosis to steatohepatitis could be mediated by increased oxidative
stress in the absence of an upregulate antioxidant response to this stress. Since the HFD increases
lipid peroxides, mitochondrial dysfunction and ER stress, the loss of the antioxidant defense system
would leave the hepatocyte compromised and susceptible to necrosis (3, 157). This effect would
not require the generation of active PCB intermediates via cytochrome P450 metabolism, that
would need to be detoxified by glutathione conjugation and may explain how the effect occurs in
either PCB 153 and now Aroclor 1260 exposed mice when neither this congener nor the PCB
mixture is metabolized at an appreciable extent (15). Finally, this EGFR-NRF2 signaling pathway
has been well characterized in C. elegans, but not in mammalian livers (158) and our observations
indicate that this pathway is very likely conserved.
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Our data suggest that Aroclor exposure alone in vivo can activate HSCs, but it was more
pronounced in the livers of mice fed a HFD and exposed to PCBs. In cell culture models, PCBs
did not directly activate HSCs. PCBs however did stimulate HepG2 cells to increase expression of
the potent HSC activating factor, TGF-b. MEF2C, which was predicted to be upregulated in the
livers of mice that develop steatohepatitis was elevated at the RNA level and maximum in mice that
developed steatohepatitis. MEF2C is an HSC transcription factor that regulates fibrotic gene
expression upon HSC activation (159). These data suggest that PCB exposures can promote a
fibrotic response through a mechanism involving TGF-β production from hepatocytes and MEF2C
upregulation. While histologically liver fibrosis was not increased in this model it has been reported
in other PCB exposure models that have either longer periods of PCB exposures and/or certain
dietary conditions (3, 139). These data suggest that fibrosis in response to PCBs should be reevaluated in other model systems and human subjects as the data suggest PCBs promote the early
stages of fibrosis (e.g. HSC activation).

In conclusion, this study demonstrates that NRF2 and HNF4a are two EGF-sensitive
transcription factors whose activity is downregulated due to PCB exposure in steatohepatitis. Our
work demonstrates HSC activation through PCB-mediated effects on hepatocytes. This study also
demonstrated that many nuclear receptors that are clinical drug targets for NASH (e.g. FXR, LXRa,
PPARs) are downregulated with PCBs. This is the first proteomic study to characterize the effects
of PCBs in the progression from dietary steatosis to steatohepatitis and has identified three novel
findings: downregulation of NRF2 (antioxidant defense); HNF4a (liver homeostasis) effects, and
activation of HSCs (fibrotic response). Collectively, the data suggests that PCB exposure
downregulates the hepatoprotective responses making the liver susceptible to damage caused by
a HFD leading to steatohepatitis.
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CHAPTER 5

PCBs ARE SIGNALING DISRUPTING CHEMICALS THAT PROMOTE SECONDARY
NECROSIS IN TASH
INTRODUCTION
Elevated PCB body burden in residents of the Anniston, AL cohort is positively associated
with liver necrosis marker cytokeratin 18 (KRT18) (13). In animal models that mimic these human
exposures, the development of PCB-mediated toxicant associated steatohepatitis (TASH) is
contingent upon both the exposure and feeding of a high fat diet (HFD). PCB exposure has been
shown to elicit a transcriptional response of xenobiotic metabolizing genes mediated through the
constitutive androstane receptor (CAR) (22, 90-92). PCBs were considered direct CAR agonists,
but my recent work has demonstrated that they may also act through epidermal growth factor
receptor (EGFR) inhibition leading to CAR activation (96, 140). EGFR is a receptor tyrosine kinase
that is highly expressed in the liver but little is known about its physiological role in liver homeostasis
and metabolism (24). EGFR can regulate the phosphorylation state of many downstream targets
including, but not limited to CAR, hepatocyte nuclear factor 4 alpha (HNF4a), and nuclear factor
(erythroid-derived 2)-like 2 (NRF2) (19). Deficits in cell signaling has a continued relevance in
metabolic disease with loss of insulin signaling and diabetes being the strongest example (160).
Loss of other signaling pathways in the context of metabolic disease are understudied and may be
just as critical as insulin signaling. Kinase inhibition is tightly associated with cell death and is
possibly a key event in the development of steatohepatitis. To characterize the complexity of PCBmediated signaling disruption in the liver, a phosphoproteomic approach was used. In this study, I
aimed to characterize the dietary and PCB-mediated effects on the hepatic phosphoproteome in
an animal model of TASH and determine how PCBs promote cell death in TASH.
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MATERIALS AND METHODS
Animal Studies.
The C57Bl/6 (male) mouse liver samples used in this study were obtained from archived (-80°C)
tissues from a previous study (3). This study used a protocol approved by the University of Louisville
Institutional Animal Care and Use Committee. Guidelines provided by the NIH guide for the care
and use of laboratory animals were abided by for this research. In this study, three samples per
group were randomly selected and used for the proteomic study. The mice fed a HFD and treated
with Aroclor 1260 developed steatohepatitis as demonstrated by CAE and H&E staining, elevated
pro-inflammatory cytokine and liver enzymes profiles (3).
Protein Sample Preparation
Mouse liver tissue were homogenized in 1% SDS RIPA buffer. Protein lysate (100 µg) per sample
was prepared and trypsinized using the filter aided sample prep (FASP) protocol (144).
Phosphopeptides were then further enriched with TiO2 and purified using C18 columns (161).
Peptide concentrations were measured by a bicinchoninic acid assay to determine the recovery
amount to use for subsequent liquid chromatography and mass spectrometry analysis.
Liquid Chromatography
The columns used were an Acclaim PepMap 100 75µm x 2cm, nanoViper (C18, 3µm, 100Å) trap,
and an Acclaim PepMap RSLC 50µm x 15cm, nanoViper (C18, 2µm, 100Å) separating column
(ThermoFisher Scientific, Waltham, MA, USA).

An EASY-nLC 1000 UHPLC system

(ThermoFisher, Waltham, MA) was used with solvents A = 2% v/v acetonitrile / 0.1% v/v formic acid
and B = 80% v/v acetonitrile / 0.1% v/v formic acid as mobile phases. Following injection of 500ng
of sample onto the trap, separation was accomplished at 300 nL/min with a 110-minute linear
gradient from 0% B to 50% B, followed by a 5min linear gradient from 50% B to 95% B, and lastly
a 5min wash with 95% B. A 40mm stainless steel emitter (ThermoFisher, Waltham, MA) was
coupled to the outlet of the separating column. A Nanospray Flex source (ThermoFisher, Waltham,
MA) was used to position the end of the emitter near the ion transfer capillary of the mass
spectrometer. The ion transfer capillary temperature of the mass spectrometer was set at 225°C,
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and the spray voltage was set at 1.6 kV.

Other chromatography settings are provided as

supplemental material.
Mass Spectrometry
An Orbitrap Elite – ETD mass spectrometer (ThermoFisher) was used to collect data from the LC
eluate. An Nth Order Double Play was created in Xcalibur v2.2. Scan event one of the methods
obtained an FTMS MS1 scan (normal mass range; 240,000 resolution, full scan type, positive
polarity, profile data type) for the range 300-2000m/z. Scan event two obtained ITMS MS2 scans
(normal mass range, rapid scan rate, centroid data type) on up to twenty peaks that had a minimum
signal threshold of 5,000 counts from scan event one. The lock mass option was enabled (0% lock
mass abundance) using the 371.101236m/z polysiloxane peak as an internal calibrant. Other
method settings are provided as supplemental information.
Data Analysis with Peaks Studio 7.5
The raw data files were analyzed separately with Peaks Studio 7.5 using the UniprotKB mouse
reviewed canonical and isoform protein sequences current as of 3/21/2017 and the Denovo,
PeaksDB, and PeaksPTM algorithms. Identifications at the 1% FDR threshold from the PeaksDB
and PeaksPTM results were loaded into the Peaks Label Free Quantification algorithm. Other
analysis settings are provided as supplemental information. Data files for acquired LCMS data
(.RAW), search engine files (.mgf), peak list files (.mzML) files, and search results aggregated into
a

Scaffold3

(.sf3,

ProteomeSoftware.com)

will

be

deposited

with

MassIVE

(http://massive.ucsd.edu/) data repository with the Center for Computational Mass Spectrometry at
the

University

of

California,

San

Diego

and

shared

with

the

ProteomeXchange

(www.proteomexchange.org).
MetaCore Analysis
Proteins with significantly different abundances (p<0.05) with a HFD, Aroclor exposure, or
interaction were analyzed with MetaCore pathway, processes, and pathology ontologies. Only
pathways, processes, pathologies identified with a false discovery rate (FDR) less than or equal to
0.05 were accepted.
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PhosphoScanSite Analysis
Phosphosites were searched using the Massachusetts Institute of Technology’s free software
PhosphoScansite 3. Low, medium, and high stringency thresholds were used to identify potential
kinases that regulate these phospho-substrates.
Cell Culture.
Primary human hepatocytes obtained from BioreclamationIVT supplemented with Invitrogro
Hepatocyte Media and Torpedo antibiotic solution (BioreclamationIVT, Westbury, NY). The cells
were plated on collagen plates and incubated in a 5% carbon dioxide atmosphere and 95%
humidity at 37° C.
Cellomic Cell Death Assay
Primary human hepatocytes were exposed to either 0.5% DMSO or Aroclor 1260 (10 µg/mL) for 6
and 24 hours. At each time point cells were stained with Hoechst 33342 (Thermo-Scientific,
Waltham, MA) and imaged. Data for DNA fragmentation percent (Cells below 2N DNA content) and
nuclear area were taken at each time point. Apoptosis and necrosis demonstrate DNA
fragmentation but apoptotic nuclei are smaller, thus enabling these two factors to be used to
distinguish between live, apoptotic, and necrotic cells (162).
Western Blot Analysis.
Mouse liver lysates were homogenized in RIPA Buffer (100 mg tissue/0.5 mL RIPA supplemented
with protease, and phosphatase inhibitors 10 µl/mL, (Sigma-Aldrich, St. Louis, MO)). The following
primary antibodies were used: CK2a, CK2 phosphosubstrate, PP2a, and CASP3 (Cell Signaling
Technology, Danvers, MA); CK2b, PTP1B, S150 CASP3 (abcam Cambridge, UK). Full description
of western blot analysis can be found in chapter 2.
Statistical Analysis. Western blot densitometry values, quantified RNA values were statistically
analyzed using GraphPad Prism Version 7 for Macintosh (San Diego, CA). The data are expressed
as box and whisker plots. Data was compared using two-way ANOVA. P<0.05 was considered
statistically significant. Quantified peptides were statistically compared by two-way ANOVA with a
looping two-way ANOVA script in R software package.
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RESULTS
Phosphoproteomic analysis identifies phosphorylated substrates altered by a HFD, Aroclor
exposure, and their interaction.

Due to PCBs being demonstrated to be hepatic EGFR

antagonists and EGFR regulates many downstream targets in the liver, an unbiased
phosphoproteomic approach was implemented to identify the effects of diet and PCBs on the
hepatic phosphoproteome. Fig 24A Illustrates the phosphoproteomic workflow and analysis of
murine liver from control diet (CD) fed mice or HFD fed mice with or without exposure to Aroclor
1260 (20 mg/kg). Fig 23B demonstrates that 113 phospho-peptides were significantly increased,
while 104 were decreased due to a high fat diet. Aroclor 1260 exposure decreased levels of 131
phospho peptides and increased 46. The interaction between a HFD and Aroclor exposure
decreased 185 phospho peptides and increased only 9. A majority of the phospho-peptides are
significantly diminished with Aroclor 1260 exposure and/or interaction suggesting that PCBs are
signaling disrupting chemicals.
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Figure 24. Phosphoproteomic analysis identifies phosphorylated substrates altered by
Aroclor 1260 exposure, a HFD, and their interaction: A. Phosphoproteomic workflow is
illustrated. B. A HFD enriched 113 p-peptides and diminished 104 p-peptides. Aroclor 1260
exposure enriched 46 p-peptides and diminished 131. The interaction of the two variables enriched
9 p-peptides and diminished 185. Phospho-peptide abundances were compared by two-way
ANOVA and only peptides that were significantly changed (P<0.05) were investigated further.
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MetaCore pathway, processes, and pathology analysis of significant peptides
Proteins with significant different abundances of phosphosites due to a HFD, Aroclor exposure, or
their interaction were analyzed with MetaCore ontologies. Table 7A demonstrates that a HFD
affected ontologies involved in lipid accumulation, adiponectin signaling, and lipoprotein assembly.
Table 7B illustrates that Aroclor exposure affects pathways involved in PI3K, insulin, and LXR
signaling. Table 7C demonstrates that HFD and Aroclor interaction affected liver necrosis and
protein chaperones.
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Table 7: MetaCore pathway, processes, and pathology analysis of peptides affected by a
HFD, Aroclor, and their interaction A. Ontologies affected by a HFD, B. Aroclor exposure, and
C. interaction. Phospho-peptides that were significant by two-way ANOVA were used for this
analysis and only pathways that met the FDR of 0.05 were used.
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PhosphoScanSite 3 analysis of the significant phosphopeptide demonstrates that many
kinases are downregulated with Aroclor exposure and the Aroclor and HFD interaction.
Using the significant p-substrates and the direction of their abundance was altered due to
experimental variables, a kinome analysis was conducted. Fig 25A demonstrates that some
kinases were predicted to have higher activity, while others were lower with a HFD. Fig 25B shows
that a majority of the kinases are predicted to have lower activity with Aroclor exposure. Fig 25C
suggests that all of the kinome is downregulated due to the interaction of a HFD and Aroclor
exposure. This would suggest that in the development of TASH, loss of phosphoprotein signaling
is a key step.
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Figure 25: PhosphoScanSite 3 analysis of the significant phosphpeptides demonstrates that
many kinases are downregulated with Aroclor exposure and the Aroclor and HFD interaction
A. The kinome changes predicted to be altered by a HFD, B. Aroclor exposure, C. or interaction.
P-peptides that were significantly different by two-way ANOVA were used in the PhosphoScanSite
3 analysis to determine what kinase regulates the substrate.
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PP2a and PTP1b were not significantly upregulated with Aroclor exposure suggesting the
cumulative loss of phosphoprotein signaling is due to loss of signaling. Since the levels of
protein phosphorylation are dramatically downregulated with PCB exposure and with dietary
interaction, the expression of phosphatases was assessed. Fig 26A-B demonstrate that Ser/Thr
phosphatase PP2a and Tyr phosphatase PTP1B were not significantly changed with PCB
exposure or diet. This suggests that the loss of phosphoproteins and kinase activity cannot be
explained by increased phosphatase levels, but loss of activation through phosphorylation.
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Figure 26. PP2A and PTP1b were not significantly upregulated with Aroclor exposure
suggesting the cumulative loss phosphoprotein signaling is due to loss of phosphorylation.
A. Immunoblot analysis of hepatic PP2a and B. PTP1B. A n=5 was used for the immunoblot
analysis. A two-way ANOVA was used to statistically compare these datasets.
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Aroclor exposure diminishes CK2 activity and reduces expression of the a and b subunits
but increases the expression of the a’ subunit. Since CK2 was projected to have decreased
kinase activity after Aroclor exposure, CK2 activity and the pattern of expression of its subunits
were measured. CK2 can function as a tetramer and is thought to be constitutively active, but little
is known in regard to the subunit configuration on kinase activity (163, 164). Fig 3A-D demonstrates
that Aroclor exposure diminishes the protein expression of CK2a 97% (p<0.01), and CK2b 67%
(p<0.01), and CK2 kinase activity 81% (p<0.002) (CD vs CD+) but increases the expression of
CK2a’ (p<0.0006). The expression of CK2a’ is most pronounced in the livers of mice that developed
TASH. CK2 can function as a tetrameric enzyme with either 2 alpha subunits and 2 beta subunits
or 2 alpha’ subunits and two beta subunits. Interestingly PCB exposure promotes CK2 alpha’
subunit expression which is more pronounced with a HFD and PCB exposure.
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Figure 27. Aroclor exposure diminishes CK2 activity and reduces expression of the a and b
subunits but increases the expression of the a’ subunit A. Immunoblot analysis of CK2a, B.
CK2a’, C. CK2b expression, and D. CK2 phospho-substrate. E. Illustration of alterations in CK2
subunit expression relative to CD expression. A n=5 was used for the immunoblot analysis. A twoway ANOVA was used to statistically compare these datasets.
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Aroclor exposure prevents CASP3 phosphorylation and promotes secondary necrosis in
vitro.

CK2 negatively regulates cell death through phosphorylation of caspases at residues

surrounding their cleavage sites, thereby, preventing caspase-mediated cell death. Since TASH is
distinguished by elevated hepatic cell death and there is a loss of CK2 activity with PCB exposure,
caspase-3 (CASP3) phosphorylation and cell death were measured. In Fig 4A CASP3 expression
is actually reduced 59% (p<0.0003) with PCB exposure or a HFD 63% (p<0.0001) and its decline
is more pronounced with the co-exposure (31%) (p<0.0016) relative to CD expression. Fig 4B
demonstrates that phosphorylation of CASP3 at S150 is downregulated with Aroclor exposure
(52%) (p<0.006), HFD (49%)(p<0.02), and their interaction (40%)(p<0.0005). (Fig 4C). Primary
human hepatocytes exposed to PCBs first undergo a level of apoptosis, 33.3% of cells at 6 hours
and 41.7% at 24 hours are apoptotic, followed by 4.2% of cells undergoing secondary necrosis at
6 hours, and 41.7% at 24 hours (Fig 4D). Apoptosis is the preferential method of cell death which
concludes with phagocytic clearance. Under circumstances of elevated hepatocyte cell death when
cells are not cleared secondary necrosis and inflammation can occur which is considered the full
apoptosis program (2). The dramatic loss of CASP3 expression in TASH suggest that this due to
post-apoptotic degradation which in vivo would present as necrosis due to the fleeting nature of the
process.
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Figure 28. Aroclor exposure promotes secondary necrosis in TASH A. Immunoblot analysis
of hepatic CASP3, B. S150 CASP3. C. Cellomics cell death measure in primary human
hepatocytes at 6 and 24 hours. A n=5 was used for the immunoblot analysis. A n=24 was for the
Cellomics assay, each plotted point is a mean for 2500 cells. A two-way ANOVA was used to
statistically compare these datasets.
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DISCUSSION
PCBs were previously characterized as EGFR antagonists in vivo and in vitro and coined
“signaling disrupting chemicals” providing a rationale to investigate the hepatic phosphoproteome
in an animal model of PCB-mediated TASH (140). Cell signaling through protein phosphorylation
via kinases is critical for cells to respond to intracellular and extracellular cues rapidly. The most
well characterized example of loss of hepatic signaling in metabolic disease is insulin resistance
(160). While the insulin receptor is one of the most well studied RTKs in metabolism, EGFR is
highly expressed in the liver and is under-studied in the context of NAFLD.
The MetaCore analysis demonstrated that a HFD affects hepatic lipid accumulation which
is well-established in many HFD fed animal models (67, 165). Aroclor was found to affect pathways
involving PI3K, insulin and LXR which has previously been demonstrated with PCB exposures in
the liver (13, 96, 140). The interaction of a HFD and PCB exposure promoted liver necrosis which
reproduces previous findings (18, 36, 166).
Interestingly, a majority of the hepatic phosphopeptides were significantly decreased with
Aroclor exposure and the PCB-dietary interaction. Roughly, a quarter of the phosphopeptides were
diminished in the livers of mice that developed TASH suggesting loss of cell signaling could be a
key to the development of TASH. When analyzing the kinome alterations due to the experiment
variables, Aroclor exposure suppressed all kinase activity and the Aroclor-HFD interaction
exacerbated this effect. Some of these effects have been validated previously, such as, loss of AktmTOR and ERK signaling due to PCB exposure (96, 140). Since protein phosphorylation can be
regulated by kinases and phosphatases, the abundance of serine/threonine/tyrosine phosphatases
were determined.
The initial observation of profound loss of protein phosphorylation in TASH due to Aroclor
exposure was followed by measurement of phosphatases to determine whether their expression is
higher with exposure or if cell signaling by phosphorylation is lost. Interestingly, serine/threonine
phosphatase PP2A and a tyrosine phosphatase, PTP1B, had decreased or were unchanged in
expression with PCB exposure in TASH. This would suggest that the loss of protein
phosphorylation is due to a loss of regulation by phosphorylation and not an upregulation of

104

phosphatases activity. One kinase not previously demonstrated to be downregulated by PCBs in
the development of TASH was CK2.
CK2 has been shown to negatively regulate cell death through phosphorylation of residues
surrounding caspase cleavage sites, thereby, preventing cleavage (167). CK2 is unique, in that it
is made up of subunits and is considered constitutively active (163, 164). CK2 is thought to be
constitutively active in order to prevent incidental caspase-mediated apoptosis through caspase
phosphorylation by CK2 (164, 168). The data suggested that hepatic CK2 activity is decreased
during Aroclor exposure. Our validation experiment confirmed this initial observation and
demonstrated that the subunit composition is altered with PCB exposure, resulting in an inhibitory
effect on kinase activity. Interestingly with PCB exposure, the CK2a’ subunit was more highly
expressed, and this was further increased in mice that were exposed and fed a HFD, clearly
demonstrating an interaction unique to TASH. CK2a’ is a key effector kinase in interleukin-6 and
tumor necrosis factor alpha signaling in inflammation which may explain the elevated expression
with PCB exposure (169). Also CK2b is downregulated with Aroclor exposure, as well, which has
been shown to be required for the tetrameric formation (163). CK2 is the main regulator CASP3
phosphorylation that negatively regulates apoptosis through prevention of CASP3 self-cleavage
and activation (167, 168, 170).
CASP3 is a measure of apoptotic cell death that can be due to intrinsic or extrinsic
activation (167, 170). Apoptosis is a programmed form of cell death that is often considered noninflammatory, as opposed to necrosis (171). Recent data demonstrates that in liver disease models,
apoptosis is the initial cell death mechanism observed, but once immune cell-mediated apoptotic
cell clearance is saturated (or no immune cells are present as seen in in vitro models), secondary
necrosis occurs (2). Our data supports this model as CASP3 expression is decreased relative to
control with either PCB exposure or a HFD suggesting it is undergoing post-apoptotic degradation.
This is further exacerbated in the livers of mice fed a HFD and exposed to PCBs. In primary human
hepatocytes exposed to Aroclor 1260, cell apoptosis is first observed at 6 hours, followed by a rise
in necrotic death at 24 hours. Since this a rapid PCB effect it would present as necrosis in vivo.
These findings suggest that PCB exposure promotes apoptosis followed by secondary necrosis.
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This adds support to human studies where elevated whole CK-18 (necrosis marker) in serum is
associated with PCB load in exposed populations (13).
This is the first phosphoproteomic analysis of an animal model of TASH. Collectively, the
data suggest that loss of protein phosphorylation and down-regulation of the hepatic kinome is a
major factor in the development of PCB-mediated TASH. This study confirms past studies in PCBs
downregulated hepatic AKT, ERK, and mTOR activity. CK2 is one is downregulated in TASH, due
to PCB exposure promoting loss of CK2a and CK2b subunit expression. PCB-mediated loss of
CK2 activity prevents negative phospho-regulation of CASP3. Secondary necrosis appears to be
the final mechanism of cell death in PCB-mediated TASH in vivo and in vitro.
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CHAPTER 6

THERAPEUTIC EFFICACY OF EGF ADMINSTRATION IN PCB-MEDIATED
STEATOHEPATITIS AND FIBROSIS

INTRODUCTION

PCBs have been demonstrated to act in part through EGFR inhibition in vitro and in vivo in
the development of steatohepatitis. PCB exposures act in part to disrupt the EGFR regulation of
the proteome and phosphoproteome but many of the mechanisms of PCBs acting through EGFR
inhibition have been correlative and not causative in the NAFLD pathogenesis. It is not currently
known whether EGF administration can prevent the development of NAFLD in mice exposed to
PCBs. I postulate that EGF administration can rescue hepatic EGFR signaling preventing some of
the PCB-mediated pathology previously observed, namely steatohepatitis (3, 18, 166). In this study
I aimed to I) determine if EGF administration can rescue hepatic EGFR signaling in PCB-exposed
mice, II) determine if EGF administration can prevent either PCB-induced steatohepatitis and or
diet induced steatosis as well as fibrotic response.

MATERIALS AND METHODS
Animal Studies
All animal procedures were previously approved by the University of Louisville IACUC and all
animals were treated humanely as documented in the “Guide for the Care and Use of Laboratory
Animals: Eight Edition” (143). C57Bl/6 male mice (8-10 weeks old) were exposed to either corn oil
or Aroclor 1260 (20 mg/kg) by a one-time oral gavage at week 1 (n=17 per group). Mice were fed
a 42% HFD (Envigo, Huntingdon, UK) ad lib. At week 10 mice were either injected with EGF
(0.2µg/g) or saline via i.p. once a day for 5 days on week 10 and an additional 5 days of week 11.
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Mice were then euthanized via intraperitoneal injection of ketamine/xylazine at 120/16 mg/kg.
Mice groups are labeled CS for corn oil gavage with saline injection, CE for corn oil gavage with
EGF injection, AS for Aroclor 1260 gavage with saline injection, or AE for Aroclor 1260 gavage
with EGF injection.

A separate group of C57Bl/6 mice (8-10 weeks old) were exposed to either corn oil or Aroclor 1260
(20 mg/kg) by a one-time oral gavage at week 1 (n=5 per group). Mice were fed a control diet
(Envigo, Huntingdon, UK). At week 2 mice were either injected with EGF (0.002, 0.02, 0.2µg/g) or
saline via i.p After 30 minutes mice were then euthanized via intraperitoneal (i.p.) injection of
ketamine/xylazine 120/16 mg/kg. Serum was extracted, and serum pyruvate and glucose were
measured.

Glucose tolerance test (GTT) and Insulin Tolerance Test (ITT

)At week 11 mice were fasted for 6 hours and had their fasting blood glucose levels measured with
a glucometer (Accu-Check Aviva, Roche, Basel Switzerland). Mice were then injected with insulin
(0.5 U/kg) via i.p. injection to perform an ITT. Blood glucose levels were then measured at 15, 30,
60, and 120-minute intervals.

At week 12 mice were fasted for 18 hours and had their fasting blood glucose recorded with a
glucometer. Mice were then injected with glucose (1 mg/g of body weight in sterile saline) via i.p.
injection. Blood glucose levels were then measured at 15, 30, 60, and 120-minute intervals.

Liver histological analysis

Liver sections were fixed with 10% neutral buffered formalin and embedded in paraffin. Sections
were stained with hematoxylin-eosin (H&E) or for chloroacetate esterase (CAE) activity (Napthol
AS-D Chloroacetate [Specific Esterase] kit, Sigma Aldrich (St. Louis, MO), or Picro-Sirius Red stain
for collagen deposition and fibrosis, Sigma Aldrich (St. Louis, MO). Slides were examined by light
microscopy at 20X or 10X and imaged.

108

Serum cytokine, adipokine blood biochemistry measurement

A Milliplex Serum Adipokine kit was used to measure serum adiponectin, tumor necrosis factor
alpha (Tnfa), resistin, and plasminogen activator inhibitor-1 (PAI-1) on the Luminex IS 100
instrument (Luminex Corp, Austin, TX). Serum low density lipoprotein (LDL), high density
lipoprotein (HDL), triglycerides, glucose, and total cholesterol were measured on the Piccolo
Xpress Chemical Analyzer using a Lipid Panel Plus reagent disc (Abaxis, Union City, CA)

Serum pyruvate and free fatty acid measure

Serum pyruvate was measured spectrophotometrically by the loss of nicotinamide adenine
dinucleotide (NADH) absorbance at 340 nm in the presence of lactate dehydrogenase. A standard
curve was used to determine the exact concentration in each sample.

Serum free fatty acids were measured with the Free Fatty Acid Quantification Kit purchased from
Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO)

Hepatic cholesterol, triglycerides (TGs) and free fatty acid (FFA) measurements

Liver tissue was homogenized in phosphate buffer saline (PBS) and lipids were extracted with a
3:1 chloroform to methanol separation method (172). The lipid extract was dried and suspended in
either Infinity Cholesterol Stable Reagent, Infinity Triglyceride Stable Reagent (Fisher Diagnostics,
Middletown, VA), or free fatty acid assay buffer (Sigma-Aldrich, St. Louis, MO) and the absorbance
was measured relative to lipid standard curves.

Western Blot Analysis

Mouse liver lysates were homogenized in RIPA Buffer (100 mg tissue/0.5 mL RIPA supplemented
with protease, and phosphatase inhibitors 10 µl/mL, (Sigma-Aldrich, St. Louis, MO)). Primary
antibodies used include EGFR (Santa Cruz, Dallas, TX ), Y1173 EGFR (abcam Cambridge, UK),
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CAR (abcam Cambridge, UK), b-actin (CST Danvers, MA), and the secondary HRP antibody (CST
Danvers, MA). Full description of western blot analysis methods can be found in chapter 2.

Real time quantitative polymerase chain reaction (RT qPCR)

Mouse livers were homogenized, and total RNA was extracted using the RNA-STAT 60 protocol
(Tel-Test, Austin, Texas). Taqman Gene Expression Assays (Thermo-Fisher) Gene expression
levels were calculated according to the 2-DDCt method, and Gapdh was used as the endogenous
control. The following Taqman Probes were used Apolipoprotein B (ApoB), Mm01545159_m1;
Cluster of differentiation 68 (Cd68), Mm03047343_m1; Cytochrome P450 Family 2 Subfamily B
Member 10 (Cyp2b10), Mm01972453_m1; Cytochrome P450 Family 3 Subfamily A Member 11
(Cyp3a11),

Mm00731567_m1;

Glyceraldehyde-3-phosphate

dehydrogenase

(Gapdh),

Mm99999915_g1; Interleukin-6 (Il-6), Mm00446190_m1; Lymphocyte antigen 6 family member 6D
(Ly6g6d), Mm00459644_m1; Myocyte enhancer factor 2c (Mef2c), Mm01340842_m1; Nuclear
receptor Subfamily 1 Group I Member 3 (Nr1i3), Mm01283980; Toll like receptor 4 (Tlr4),
Mm00445273_m1; Transforming growth factor beta (Tgfb), Mm01227699_m1; Tumor necrosis
factor alpha (Tnfa), Mm00443258_m1.

Statistical Analysis. Western blot densitometry values, quantified RNA values, macromolecule
measures, and other biological measures were statistically analyzed using Graphpad Prism
Version 7 for Macintosh (San Diego, CA). The data are expressed as box and whisker plots. Figures
30 Ai, Bi, Ci, Di are represented as mean±SEM. Data was compared using two-way ANOVA. A pvalue<0.05 was considered statistically significant.
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RESULTS

EGF rescues hepatic EGFR signaling in PCB-exposed mice and downregulates CAR
activation

Since PCBs have been shown to inhibit hepatic EGFR signaling which coincided with the
development of steatohepatitis a therapeutic study was implemented to determine if the PCBmediated effects were through EGFR inhibition in vivo and if they could be countered by EGF. First
the effects of EGF and Aroclor 1260 exposure were on hepatic EGFR phosphorylation were
measured to validate our model system. In Figure 29A western blot analysis of whole liver
demonstrates that EGFR phosphorylation at Y1173 is elevated with EGF administration even in
mice exposed to PCBs. In un-exposed mice EGF administration elevated EGFR phosphorylation
46% (CS vs. CE) in Aroclor exposed mice EGF administration elevated EGFR phosphorylation
55% (AS vs. AE, p<0.04). Since PCBs are proposed to act through EGFR inhibition indirectly
activating CAR, CAR expression and target geneexpression were measured. Fig 29B western blot
analysis of whole liver demonstrates that CAR protein expression is not altered with any exposure
or treatment. Fig 29C shows that qPCR analysis of total liver RNA demonstrates that CAR gene
expression is elevated 14% with EGF (CS vs. CE, p<0.04) and 34% with PCB exposure (CS vs.
AS, p<0.0001). As reported by Wahlang et al 2014 (3) PCB exposure increased Cyp2b10 mRNA
by 51%. CAR’s target gene Cyp2b10 is downregulated 35% due to interaction of EGF and PCB
exposure suggesting PCB-mediated indirect CAR activation likely occurs through inhibition of
EGFR phosphorylation (p<0.05) Cyp3a11 mRNA was significantly elevated 32% by Aroclor
exposure (CS vs. AS, p<0.04) but is diminished 25% with EGF treatment (AS vs. AE) suggesting
CAR activation is negatively regulated by EGFR signaling.
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Figure 29. EGF rescues hepatic EGFR signaling in PCB-exposed mice and downregulates
CAR activation: Immunoblot analysis of A. hepatic EGFR protein phosphorylation at Y1173 and
B. CAR in mice gavaged with corn oil and injected with either saline (CS) or EGF (0.2 µg/g) (CE)
or gavaged with Aroclor 1260 (20 mg/kg) and injected with saline (AS) or EGF (AE). C. qPCR
analysis of hepatic Car, Cyp2b10, and Cyp3a11 mRNA expression. An n=5 was used for figures
28A-B and an n=17 was used for figure 28C. A two-way ANOVA was used to statistically compare
datasets. A p<0.05 was considered significant. Significance due to EGF is denoted by a, due to
Aroclor denoted by b, and due to interaction denoted by c. Data are represented as box and whisker
plots.
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EGF promotes hepatic gluconeogenesis and reduces insulin sensitivity but does not affect
glucose uptake
Hepatic EGFR signaling peaks in the inactive phase or fasted state in mice which suggests it may
have a regulatory role in glucose metabolism that could be altered due to PCB exposure (28). In
Fig 30Ai EGF administration promotes elevation of blood glucose levels at all doses of EGF, while
in Fig 30Aii, EGF was shown to elevate fasting blood glucose levels 17% in non-exposed mice (CS
vs. CE) and 31% in exposed mice (AS vs. AE) after a 18 hour fast suggestive of increased hepatic
gluconeogenesis (p<0.007). Fig 30Bi demonstrates EGF increases pyruvate uptake after 30
minutes in male C57Bl/6 mice. Fig 30Bii shows that Aroclor exposure promotes elevated serum
pyruvate 61% (CS vs. AS) in the 12-week study (p<0.0001). Fig 30Ci-ii illustrates that neither EGF
nor PCBs affect glucose uptake in a GTT. Fig 30Di-ii demonstrates that EGF administration
reduces insulin sensitivity in an ITT. These data support that EGF is glucogenic in the liver and that
Aroclor exposure to some extent can potentially prevent EGF-stimulated hepatic uptake of the
glucogenic substrate pyruvate.
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Figure 30. EGF promotes hepatic gluconeogenesis and reduces insulin sensitivity but does
not affect glucose uptake: Ai. Serum glucose and serum pyruvate Bi were measured in mice
treated with EGF (0.002, 0.02, 0.2µg/g) or saline control for 30 minutes. Aii serum glucose and
serum pyruvate Bii were measured in mice gavaged with corn oil and injected with either saline
(CS) or EGF (0.2 µg/g) (CE) or gavaged with Aroclor 1260 (20 mg/kg) and injected with saline (AS)
or EGF (AE). Ci-ii GTT’s were performed in the CS,CE, AS, AE mice as well as Di-ii ITT’s. A n=5
was used for figures 30Ai and 30Bi. An n=17 was used for figures 30Aii, 230Bii, 30C and 30D. A
two-way ANOVA was used to statistically compare datasets. A p<0.05 was considered significant.
Significance due to EGF is denoted by a, due to Aroclor denoted by b, and due to interaction
denoted by c. Data are represented as mean±SEM for figures 30Ai, Bi, Ci, Di, but are represented
as box and whisker plots for figures 30Aii, Bii, Cii, and Dii.
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EGF promotes lipid redistribution to adipose tissue in Aroclor exposed mice
Previously PCB exposure was not demonstrated to worsen steatosis in mice fed a HFD but
elevated EGFR signaling in mice fed a HFD has been shown to be protective (173). To characterize
the effects of PCBs and EGF on steatosis and dyslipidemia, multiple metabolic measures were
performed. H&E staining of liver sections (Fig 31A) demonstrates reduced levels of steatosis (47%
normal, <5% steatosis) in CE mice in contrast to all steatotic livers in CS mice. In Aroclor exposed
mice, EGF administration did not reduce steatosis as in control mice. Fig 31B demonstrates that
PCBs and interaction with EGFR elevated hepatic triglycerides (TGs) 42% (CE vs. AE, p<0.03, and
p<0.006 respectively), while EGF (p<0.0003), Aroclor (p<0.0003), and interaction (p<0.0005)
elevate serum TGs 31% (CS vs. AE). EGF administration diminishes hepatic FFAs 32% (CS vs.
CE, p<0.01, Fig 30C), while Aroclor exposure increases hepatic FFAs 52% (CS vs. AS, p<0.02),
but does not significantly change serum FFAs. As seen in Fig 31C, EGF increases hepatic
cholesterol levels 25% (CS vs. CE, p<0.009) but serum cholesterol is only elevated 8.7% due to
interaction (CS vs. AE, p<0.0002). Fig 31Di-v demonstrates that serum (31Di) HDL and (31Dii) LDL
are increased 4.6%(p<0.0002) and 2.4% (p<0.0034) due to interaction respectively (AS vs. AE).
While serum (31Diii) VLDL is elevated 28% (CS vs. AE) due to EGF (p<0.001), Aroclor 1260
(p<0.002), and interaction (p<0.003) between EGF and PCBs, and hepatic ApoB mRNA (31Dv)
was elevated 23% (CS vs. AE) due to EGF (p<0.0006), Aroclor (p<0.0001), and interaction
(p<0.0001). Since adipokines are diagnostic markers for steatosis the serum levels of adiponectin
(negatively associated with steatosis), resistin, and PAI-1 (positively associated with steatosis)
were measured (174). Fig 31Ei-v shows that Aroclor (p<0.0009) diminished EGF upregulation of
adiponectin (31Ei) 56% (CE vs AE, p<0.007). EGF diminished lipokines (31Eii) PAI-1 (p<0.03)
35%, and (31Eiii) resistin (p<0.03) 17% (AS vs. AE). The weight of the epididymal fat pad
normalized to body weight was measured to determine the effects of EGF and PCBs on lipid
storage in the adipose. (Figure 31Ev). Fat to body weight ratios were elevated 21% due to
interaction (AS vs. AE, p<0.02) suggesting that lipids are not adequately stored in the adipose
tissue in mice exposed to Aroclor alone.
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Figure 31. EGF promotes lipid redistribution to adipose tissue in Aroclor exposed mice: A.
H&E staining of liver section in mice orally gavaged with corn oil and injected with either saline (CS)
or EGF (0.2 µg/g) (CE) or gavaged with Aroclor 1260 (20 mg/kg) and injected with saline (AS) or
EGF (AE). B. Hepatic measures of (i)cholesterol, (ii)triglycerides, and (iii) FFAs in CS, CE, AS,
and AE mice. C. Serum measures of (i)cholesterol, (ii)triglycerides, and (iii) FFAs in CS, CE, AS,
and AE mice. D. Serum measures of (i) HDL, (ii) LDL, and (iii) VLDL in CS, CE, AS, and AE mice.
(v) qPCR analysis of hepatic ApoB mRNA expression in CS, CE, AS, and AE mice. E. Serum
measures of (i) adiponectin, (ii) PAI-1, and (iii) resistin in CS, CE, AS, and AE mice. (v) Weight of
epididymal white adipose tissue normalized to total body weight in CS, CE, AS, and AE mice. An
n=17 was used for figures 31A-E. A two-way ANOVA was used to statistically compare datasets.
A p<0.05 was considered significant. Significance due to EGF is denoted by a, due to Aroclor
denoted by b, and due to interaction denoted by c. Data are represented as box and whisker plots
for figures 31A-E.
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EGF reduces PCB-induced steatohepatitis and bridging fibrosis
PCBs have previously been shown to cause steatohepatitis in mice fed a HFD and to cause
bridging fibrosis in mice fed a methionine choline deficient diet (MCD)(3, 18, 139). In others models
of liver disease, EGF has been shown to be anti-inflammatory but it has never been tested in an
animal model of TASH (32). To assess the effects of EGF and Aroclor exposure on steatohepatitis
and fibrosis histological measures, cytokine measures, and qPCR analysis were used. In Fig 32A,
CAE staining of liver section demonstrates that EGF reduced neutrophil infiltration in Aroclorexposed mice treated with EGF. Serum Tnfa is diminished 32% with EGF (AS vs. AE, p<0.02) (Fig
2B). In Fig 32C, hepatic Tnfa mRNA is shown to be decreased 51% with EGF and PCB interaction
(AS vs. AE, p<0.03). Hepatic inflammatory gene markers Il-6 (71%, p<0.0001), Ly6gd (41%,
p<0.001), Cd68 (35%, p<0.001), and Tlr4 (42%, p<0.05) were all diminished with EGF (AS vs. AE).
Fig 32D shows the Picro-sirius red staining of liver sections demonstrating that EGF downregulates
PCB-mediated bridging fibrosis. Fig 32E demonstrates that EGF diminishes hepatic Tgf-b gene
expression 17% (AS vs. AE, p<0.01) while EGF diminishes Aroclor elevation of Mef2c expression
by 23% (AS vs. AE, p<0.003).
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Figure 32. EGF reduces PCB-induced steatohepatitis and bridging fibrosis: A. Chloroacetate
esterase activity staining in liver sections of mice orally gavaged with corn oil and injected with
either saline (CS) or EGF (0.2 µg/g) (CE) or gavaged with Aroclor 1260 (20 mg/kg) and injected
with saline (AS) or EGF (AE). B. Hepatic qPCR analysis of inflammatory gene markers mRNA
expression (Tnfa, Il-6, Ly6gd, Cd68, Tlr4) in CS, CE, AS, and AE mice. C. Serum measures of
TNFa in CS, CE, AS, and AE mice. D. Picro-sirius red staining of liver sections of CS, CE, AS, and
AE mice to detect collagen deposition. E. Hepatic qPCR analysis in CS, CE, AS, and AE mice to
measure fibrotic gene marker expression (Tgfb, Mef2c). An n=17 was used for figures 32A-E. A
two-way ANOVA was used to statistically compare datasets. A p<0.05 was considered significant.
Significance due to EGF is denoted by a, due to Aroclor denoted by b, and due to interaction
denoted by c. Data are represented as box and whisker plots for figures 32B, C, E.
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Figure 33. EGF promotes hepatic lipid packaging and export while preventing PCB-mediated
steatohepatitis and fibrosis: Model demonstrating the hepatoprotective effects of EGF
administration in Aroclor exposed mice. EGF is glucogenic and promoted lipid redistribution from
the liver to the adipose tissue in Aroclor exposed mice. EGF prevented PCB-mediated
steatohepatitis and fibrosis.
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DISCUSSION
PCBs have been shown to cause steatohepatitis in animal models and it is suggested to
occur in human populations as well (3, 13, 18). In this study previous mechanistic knowledge that
PCBs act through EGFR inhibition was applied to determine if an EGFR ligand can prevent the
pathology associated with PCB exposures, namely steatohepatitis (96, 140), in an animal model.
In our animal model, EGF administration did elevate hepatic EGFR phosphorylation even
in the Aroclor-exposed mice, while Aroclor-exposed mice had the lowest amount of EGFR
phosphorylation. Furthermore, indirect CAR activation was hindered with EGF administration, even
in the presence of PCBs suggesting that the mechanism of indirect CAR activation through PCBmediated EGFR inhibition must occur in vivo, validating our previous in vitro model systems (96,
140). While these mechanistic data support PCB-mediated EGFR inhibition, further evaluation of
EGF’s therapeutic efficacy on PCB-mediated disease endpoints were the critical findings of this
study.
Previously, EGFR signaling was found to peak in the liver in the fasted state or inactive
phase suggesting it may play a role in maintaining metabolic homeostasis for the organism when
nutrients are not being consumed (28). When mice were injected with EGF at increasing dosage
their serum glucose levels were elevated while their serum pyruvate levels were diminished relative
to saline controls. This would suggest that EGF promoted gluconeogenesis from uptake of
glucogenic substrates, such as, pyruvate. Serum pyruvate levels were elevated with Aroclor
exposure suggesting that PCBs may prevent EGFR-mediated pyruvate uptake pathway. EGFR
glucogenic effects were demonstrated before in primary hepatocytes but not in vivo (175). These
data suggest that EGFR signaling in the liver may act in part to maintain blood glucose levels in
the inactive phase. Interestingly EGF administration lowered insulin sensitivity regardless of PCB
exposure suggesting that EGFR and insulin receptor (IR) may be opposing growth factor receptors
in their effects on glucose metabolism in the liver. While insulin sensitivity was slightly lowered with
EGF administration, glucose uptake was not affected suggesting that these mice were able to
adequately handle glucose. Next, the effects of PCBs and EGF administration were analyzed in
the context of steatosis and lipid metabolism.

120

PCBs were not previously shown to affect steatosis in HFD fed-mice, but EGFR has
previously been shown to be downregulated in steatosis and could reduce fatty liver when restored
genetically (173). In non-exposed mice EGF diminished lipid accumulation and prevented steatosis
in 47% of the mice relative to saline non-exposed mice. EGF administration also reduced hepatic
free fatty acids (FFAs), but elevated hepatic cholesterol regardless of PCB exposure. PCB
exposure in contrast elevated hepatic free fatty acids and triglycerides. EGF in Aroclor-exposed
mice still develop steatosis but most of that fat appears to be packaged and redistributed to the
adipose tissue for storage. Lipid metabolism in the liver is also affected by multiple adipokines such
as adiponectin, resistin, and PAI-1 (174). PCB exposure decreased EGF’s upregulation of
adiponectin levels, the hepatoprotective adipokine that promotes hepatic beta-oxidation (176). EGF
administration reduced resistin and PAI-1 which are adipokines that worsen metabolic syndrome
(174). EGF in non-PCB treated mice seemed to reduce steatosis but in Aroclor-exposed mice it
may also be protective in reducing hepatic FFAs and promoting storage in the adipose. Since PCBs
most insidious effect previously described in the liver is the development of steatohepatitis, the
protective effects of EGF in PCB exposed mice will be discussed next (3, 18).
Steatohepatitis due to PCB-exposure has been shown to be contingent upon a HFD and
in this study mice fed a HFD and exposed to Aroclor alone do develop steatohepatitis characterized
by neutrophil infiltration, and elevated cytokine levels and expression. EGF administration
ameliorated steatohepatitis in mice exposed to PCBs. EGF’s anti-inflammatory effects in the liver
has been demonstrated previously in alcoholic liver disease models (32) but this is the first time in
an animal model of toxicant associated steatohepatitis. It is not currently known if EGF is antiinflammatory through eliciting protective effects in hepatocytes by priming them or through boosting
immune cell clearance of dying hepatocytes, thereby, reducing chronic inflammation or possibly
both. These findings suggest that EGF administration can partly prevent PCB-mediated
steatohepatitis demonstrating it’s potential therapeutic efficacy. PCB exposures in mice has been
shown to promote hepatic fibrosis in mice fed a methionine-choline deficient diet, but not previously
in HFD fed mice (139).
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In this study, only a subset of Aroclor alone exposed mice develop bridging fibrosis from multiple
portal areas characterized by collagen deposition. In mice exposed to Aroclor but treated with EGF
there was no bridging fibrosis present suggesting that EGF can be anti-fibrotic in mice exposed to
PCBs. While the bridging fibrosis due to PCB exposure alone is minor it may be exacerbated with
longer periods of exposure. Gene markers for fibrosis and hepatic stellate cells activation were
diminished with EGF treatment as well supporting its anti-fibrotic effects.
In conclusion EGF is a glucogenic growth factor that can reduce diet-induced steatosis in
HFD fed mice, unless they are exposed to PCBs. EGF treatment in Aroclor exposed mice promotes
packaging and redistribution of lipids to the adipose tissue, thereby diminishing the FFA abundance
in the liver. EGF treatment reduced PCB-mediated steatohepatitis and bridging fibrosis supporting
its potential therapeutic efficacy in this model. This work has clinical implications as there are
currently no approved therapeutics for NAFLD and EGF administration did limit multiple disease
endpoints in the liver initiated by PCB exposures or a HFD. Future study is needed to determine if
there are any adverse effects due to EGF treatment and if this therapy is beneficial in human
models of NAFLD.
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CHAPTER 7
CONCLUSIONS
In conclusion PCBs disrupt EGFR signaling in multiple model systems including murine
liver (in vivo), and murine and human hepatic cell lines (in vitro). The downstream of EGFR, effector
kinases, Akt and mTOR are all downregulated along with the expression of STAT3, and cRAF with
PCB exposure in vivo (Chapter 2).
Both NDL and DL PCBs appear to be capable of disrupting EGF endocytosis largely
through prevention of EGF binding, blocking receptor internalization. Ligand receptor modeling
suggest that PCBs can bind hydrophobic pockets within the EGF binding domain of the EGFR
preventing EGF binding. This theory is also reinforced by the fact that EGF pre-treated cells that
did not undergo endocytosis (cells on ice to prevent endocytosis) and then were exposed to PCBs
followed by incubation at 37° C still have reduced EGF endocytosis. This suggests that PCBs can
displace bound EGF from its binding pocket (Chapter 3).
PCBs can disrupt the EGFR-NRF2 signaling pathway leading to diminished total
glutathione, NRF2 target gene expression, and NRF2 protein expression. This is the first
demonstration of EGFRR regulating NRF2 in mammalian hepatic models but seems to be a
conserved pathway between C. elegans and humans. PCB exposure and a HFD interaction also
downregulate HNF4a activity and expression disrupting hepatic identity gene expression. PCBs
also promote a fibrotic response through hepatic release of fibrotic factors activating HSCs
(Chapter 4).
Phosphoproteomic analysis demonstrates that PCBs downregulate almost 25% of the
hepatic phosphoproteome in the development of TASH reinforcing the concept that PCBs act
through signaling disruption. PCBs do not elevate phosphatase expression suggesting this is purely
a loss of phosphoprotein signaling. PCB exposure also downregulate subunit expression of CK2
leading to increased CASP3 activation and initial hepatic apoptosis but ultimately secondary
necrosis in vivo and in vitro (Chapter 5.
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While findings from this research do support that PCBs do in part act through inhibition of
hepatic EGFR signaling, PCBs may act more broadly in disrupting ligand-receptor interaction of
multiple membrane receptors or limiting ligand secretion from other metabolic organs. The latter
has been supported from epidemiological studies where exposed humans have PCB dependent
decrease in leptin and insulin with increasing PCB load (13). This could in part contribute to the
limited phosphoprotein signaling capability of the liver. In essence, loss of protein phosphorylation
signaling pathways limits how the hepatocyte can react to metabolic changes leading to sustained
cell death or necrosis.
A majority of my dissertation was involved in the characterization of the PCB-mediated
effects through EGFR inhibition in the pathogenesis of NAFLD. To conclude my dissertation I
wanted to determine if I could counter the effects of PCB-mediated EGFR inhibition and if this would
be therapeutically effective in the context of NAFLD. Mice exposed to Aroclor 1260 and then treated
with EGF have improved liver function and demonstrate reduced pathology. EGF prevented PCBmediated steatohepatitis and fibrosis and promoted redistribution of lipids to the adipose tissue.
This was the first study evaluating a therapeutic regimen for TASH can has clinical impacts or the
future of NAFLD therapeutics.
In essence, my dissertation impacts two branches of science one (basic hepatology/cell
signaling) being characterization of the function of hepatic EGFR and two (mechanisms of
toxicology) elucidating an amenable mechanism of action for PCB-mediated NAFLD through EGFR
inhibition (Figure 34).
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Figure 34. PCBs act through EGFR inhibition in the pathogenesis of NAFLD: Chapter 2
demonstrates that PCBs prevent hepatic EGFR signaling in multiple model systems. Chapter 3
illustrates that PCBs can prevent EGF endocytosis potentially through prevention of EGF ligand
binding. Chapter 4 shows that PCB-mediated loss of EGFR-NRF@ and EGFR-HNF4a signaling
sensitizes the liver to NAFLD. Chapter 5 demonstrates that loss of protein phosphorylation is a key
event in the development of PCB-mediated NAFLD. Chapter 6 provides evidence that EGF
administration can prevent PCB-mediated steatohepatitis and bridging fibrosis
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APPENDIX I
SUPPLEMENTAL MATERIALS FOR CHAPTER 3
Hardesty JE, Al-Eryani L, Wahlang B, Falkner KC, Shi H, Jin J, Vivace B, Ceresa BP, Prough RA,
Cave MC. Epidermal Growth Factor Receptor Signaling Disruption by Endocrine and Metabolic
Disrupting Chemicals. Toxicological sciences : an official journal of the Society of Toxicology. 2018.
Epub 2018/01/13. doi: 10.1093/toxsci/kfy004. PubMed PMID: 29329451.
MATERIALS AND METHODS
EGF Endocytosis Assay in A-431 Cells:
This assay was modified from previously described methods (114). A-431 cells were used as they
express 2.6 ´106 epidermal growth factor receptors per cell (115). Alexa Fluor 555 labeled EGF
was purchased from Thermo Scientific, (Philadelphia, PA) and was used at 20 ng/100µL. This
concentration was used as it is it was previously shown to give robust signal in the Cellomics assay
(114). After a 3-hour serum starvation A-431 cells were exposed to varying concentrations of the
compounds (10-12 - 10-3 M) for 10 minutes. Positive control cells were treated with 0.1% DMSO and
negative control cells were treated with 20 ng/100 µL of unlabeled EGF purchased from Millipore
(Norwood, OH). This served as a negative control since the EGF receptors would be saturated and
endocytosed preventing fluorescently labeled EGF from binding thus preventing any signal. Cells
were then treated with 20 ng/100 µL of Alexa Fluor 555 labeled EGF for 30 minutes. This was
followed by 3 washes with pre-warmed PBS and incubation with 3.7% formaldehyde for 15 minutes.
Cell nuclei were then stained with Hoechst 33342 purchased from Thermo Scientific (Philadelphia,
PA) at 1 µg/100 µL for 15 minutes. Images and data were obtained via an ArrayScan HCS 4.0
Reader. Filter sets specific for Hoechst labeled nuclei and the Alexa Fluor 555-EGF were used for
detection. A 20X microscope objective was used for imaging and the SpotDetector bioapplication
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was used to acquire and analyze images. Approximately 500 cells from randomized fields were
analyzed for each well. The equation used to normalize 555-EGF count/nuclei values is listed
below.

9:;<=>?@
C ∗ 100
𝐴𝑙𝑒𝑥𝑎 𝐹𝑙𝑢𝑜𝑟 555 𝐸𝐺𝐹 𝐸𝑛𝑑𝑜𝑐𝑦𝑡𝑜𝑠𝑖𝑠 = 61 − 9AB<=>?@

This assay was also conducted with 1pM of trans-nonachlor, PCB-126, PCB-153 and 0.041 pg/100
µL of chlordane, and 100pM of atrazine either in 10% serum containing media as compared to 0%
serum media (Fig S2).

MTT Assay:
A-431 and HepG2 cells were cultured in 96-well plates as previously described. Cells were exposed
to either 0.1% DMSO (vehicle control) or the following compounds trans-nonachlor, chlordane,
atrazine, PCB-126, PCB-153, dieldrin, alachlor, lindane, DDE, or DDT at the following
concentrations 100 nM, 1 µM, 10 µM, 100 µM, or 1 mM. for 24 hours. Cells were then incubated
with MTT (0.2 mg/mL) for 3-4 hours. The formazan dye was then released by incubation with DMSO
and absorbance measured at 540 nm spectrophotometrically by the Bio-Tek Synergy HT Multimode micro plate reader (Winooski, VT).
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Figure 35. Lindane, Dieldrin, DDT, DDE, Alachlor are not potent EGFR antagonists: A.
Lindane (log IC50 = -2.1 ± 0.48), B. dieldrin (log IC50 = -4.2 ± 0.2), C. DDT (log IC50 = -4.5 ± 0.16),
D. DDE (log IC50 = -3.6 ± 0.26), and E. alachlor (log IC50 = -3.5 ± 0.27) could not prevent
fluorescent EGF endocytosis until the micromolar range. These were least potent compounds
tested and were not potent EGFR antagonists. Curves were fitted with a sigmoidal dose response
equation with GraphPad Prism 7 software. An n=8 was used for each concentration and mean ±
SEM were calculated using the equation described in methods.
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Figure 36. Pre-clearing compounds in 10% serum media does not alter EGF endocytosis in
A-431 cells: When incubating either chlordane, trans-nonachlor, PCB-126, PCB-153, or atrazine
at 1 pM with 10% serum containing media or 0% serum there is no effect on 555-EGF endocytosis.
An n=8 was used and the data are presented as mean ± SEM. A two-tailed unpaired t-test was
used to statistically compare the 10% serum vs. the 0% serum values for the select compounds. A
P*<.05 was considered significant.
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Figure 37. Cytotoxicity of trans-nonachlor, chlordane, atrazine, PCB-126, PCB-153, dieldrin,
alachlor, lindane, DDE, and DDT in HepG2 and A-431 cells: In A HepG2 and B A-431 cells the
screening library compounds do not demonstrate overt cytotoxicity until the 100 µM to 1 mM
concentration range. An n=4 was used and the data are represented as mean ± SEM. Experimental
absorbance values were normalized to a 0.1% DMSO control.
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